HOUSTON, April 22, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it has welcomed Dr. Richard Whitley to its Science Advisory Board to guide its development strategy for WP1122 for the potential treatment of COVID-19 and other viral diseases.

"Our development effort to get WP1122 into a clinical trial with COVID-19 patients is now getting into high gear," commented Walter Klemp, Chairman and CEO of Moleculin. "Among his many accomplishments, Dr. Whitley leads the Drug Discovery and Development Center for the National Institute of Allergy and Infectious Diseases, making him one of the Nation's leading authorities on the clinical development of antiviral therapies."

Richard Whitley, M.D., is a Distinguished Professor of Pediatrics, Professor of Microbiology, Medicine and Neurosurgery; Loeb Eminent Scholar Chair in Pediatrics; Co-Director, Division of Pediatric Infectious Diseases; Vice-Chair, Department of Pediatrics; Senior Scientist, Department of Gene Therapy; Scientist, Cancer Research and Training Center; Faculty, Gene Therapy Center; Associate Director for Drug Discovery and Development and Senior Leader, Pediatric Oncology Program, O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UAB); and Co-Founder and Co-Director, Alabama Drug Discovery Alliance.

Dr. Whitley is responsible for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group whose role is to perform clinical trials of antiviral therapies directed against medically important viral diseases of children and adults including viruses considered as threats to human health. He has published more than 347 articles. He participates in numerous Data Safety and Monitoring Boards for ongoing clinical studies. He is a past President of the Infectious Diseases Society of America and received the UAB President's Medal in 2007. In 2013, he was named as the inaugural recipient of the Distinguished Clinical Research Scholar and Educator in Residence at the NIH Clinical Center.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity, being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML; WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, under investigation for brain tumors, pancreatic cancer and hematologic malignancies; and WP1220, an analog to WP1066, being developed for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including additional immune/transcription modulators, as well as WP1122, a compound capable of metabolism/glycosylation disruption.

For more information about the Company, please visithttp://www.moleculin.com.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of WP1122 to demonstrate safety and efficacy in humans. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. The Company cautions investors not to place undue reliance on the interim results announced today.

ContactsJames Salierno / Carol RuthThe Ruth Group646-536-7028 / 7000jsalierno@theruthgroup.comcruth@theruthgroup.com

View original content:http://www.prnewswire.com/news-releases/moleculin-announces-head-of-niaid-antiviral-drug-discovery-and-development-center-joins-covid-19-drug-development-team-301044999.html

SOURCE Moleculin Biotech, Inc.

Original post:
Moleculin Announces Head of NIAID Antiviral Drug Discovery and Development Center Joins COVID-19 Drug Development Team - BioSpace

Recommendation and review posted by Bethany Smith

A team of investigator led by the researcher at Duke University Medical School discussed the preclinical data recently at 2019 annual meeting of the American Society of Gene & Cell Therapy.

This press release was orginally distributed by SBWire

San Francisco, CA -- (SBWIRE) -- 04/22/2020 -- TMR Research states that global gene therapy for inherited genetic disorders market will see a witness major developments in the coming years.Rapid advances in mammalian DNA sequencing technologies over the past several years have enabled the identification of the aberrant genes responsible for a vast spectrum of genetic disorders. Gene therapy as a novel approach inarguably holds profound potential in finding universal therapeutic alternatives to treating inherited genetic disorders. Gene therapy for inherited genetic disorders entails introducing a functional copy of the defective gene to make up for the missing function, and can be accomplished using in vivo or ex vivo gene transfer.

Get Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=5624

Gene therapy for inherited genetic disorders has generated groundswell of interest in the research fraternity in finding cure for or in treatment of Mendelian genetic error causing rare diseases. Particularly, gene therapy in recent years has held promising potential in the treatment of a range of recessive gene disorders most notably sickle cell anemia, hemophilia, muscular dystrophy, cystic fibrosis, and other monogenic disorders. The axes of developments in the gene therapy for inherited genetic disorders market have been in the U.S., Europe, China, and Australia.

Some of the most prominent competitors operating in the competitive landscape of global gene therapy for inherited genetic disorders market include

Spark Therapeutics Inc.Orchard TherapeuticsNovartis AGBluebird bio Inc.BioMarin PharmaceuticalGlobal Gene Therapy for Inherited Genetic Disorders Market: Notable Developments

Growing body of clinical studies done on mice models have unrivalled troves of preclinical data, which bodes well for the effectiveness of gene therapy for inherited genetic disorders. New approaches in the gene therapy for inherited genetic disorders market are being adopted to bring progress in this direction. In this regard, Salmeterol, a medicine approved for asthma, has shone a new light. The vasodilator to be used along with gene therapy has shown potential in increasing the effectiveness of the therapy for Glycogen storage disease type II (Pompe disease).

A team of investigator led by the researcher at Duke University Medical School discussed the preclinical data recently at 2019 annual meeting of the American Society of Gene & Cell Therapy. The preclinical data showed that the Asthma medicine reduces the accumulation of toxic glycogen accumulated in lysosome. The researchers concluded that it holds potential as an adjunctive therapy, and building on that may pave way for novel approaches on gene therapy for inherited genetic disorders.

Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=5624

Efforts to translate the findings of clinical research on gene therapy for inherited disorders to make the therapy a part of standard treatment has caught momentum in recent times. In this regard, vectors containing non-viral vectors have attracted the attention of scientists. A team of researchers at Fred Hutchinson Cancer Research Center in 2019 found that gold nanoparticles enable them to deliver gene-editing tools to blood stem cells in lab models. This might, they opined, pave way for more practicaland accessiblegene therapies for inherited disorders, notably for treating life-threatening blood disorders. Gene therapies were mediated by CRISPR. In the coming years they hope to collaborate with companies with commercial interest to develop the therapy for patient populations.

Global Gene Therapy for Inherited Genetic Disorders Market: Key Drivers

Since 2000, scores of clinical trials involving patients with inherited genetic disorders have raised hopes of the medical fraternity of the potential of gene therapies. Thus far, more than 5000 clinical trials on gene therapy have been conducted, especially for hard-to-treat diseases. Diseases such as inherited blindness and leukemia have seen the efficacy and safety of gene therapies. Advances in bioengineering are expected to invigorate pre-clinical pipelines. In the not-so-distant future, success of more protocols will catalyze the prospects of the gene therapy for inherited genetic disorders market.

Further, advances have been made in viral and non-viral vectors with the purpose of making gene transfer more efficient, thereby boosting the gene therapy for inherited genetic disorders market. Particularly, new approaches emerged with the aim of making vectors more powerful.

Global Gene Therapy for Inherited Genetic Disorders Market: Regional Assessment

On the regional front, Asia Pacific bears considerable potential in the gene therapy for inherited disorders market. Of note, numerous strategic alliances have shifted their focus on the region, particularly China. The North America market has also been rising at a promising pace, driven by several gene-therapy tools and related drugs in the final stages of clinical trials. Favorable reimbursement models has also encouraged research into the gene therapy for inherited disorders.

About TMR Research:TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today's supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients' conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

For more information on this press release visit: http://www.sbwire.com/press-releases/gene-therapy-for-inherited-gen/release-1288387.htm

Read more from the original source:
Gene Therapy for Inherited Genetic Disorders Market Analysis Key Players, Share Dynamic Demand and Consumption by 2018 to 2028 - Press Release -...

Recommendation and review posted by Bethany Smith

ROCKVILLE, Md., April 22, 2020 /PRNewswire/ --

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAVTechnology Platform, today provided additional long-term data from the ongoing Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD).

"I am impressed by the overall outcomes in patients after a one-time administration of RGX-314. I believe that RGX-314 is the leading gene therapy program for a major retinal disease such as wet AMD and could be an important potential one-time treatment option for AMD patients who require frequent and burdensome anti-VEGF injections. Real-world evidence demonstrates that patients lose vision over time with our current standard of care and incur significant treatment burden with frequent clinic visits and injections," said Allen C. Ho, M.D., Director of Retina Research at Wills Eye Hospital and Mid Atlantic Retina and investigator surgeon in the RGX-314 trial.

"The clinical profile of RGX-314 appears very promising as a one-time treatment strategy for wet AMD as we continue to learn about the consistent and durable effects of our anti-VEGF gene therapy," added Steve Pakola, M.D., Chief Medical Officer ofREGENXBIO. "We are encouraged that all patients in Cohort 5 who were anti-VEGF injection-free at six months remained anti-VEGF injection-free at nine months. We also have further evidence of dose-dependent intraocular protein levels in this Phase I/IIa study. We are on track to have one-year data from our later cohorts in mid-2020 and look forward to initiating a pivotal program for the subretinal delivery of RGX-314 in the second half of 2020. We are also continuing our preparations to initiate a Phase II trial for the in-office suprachoroidal delivery of RGX-314 in wet AMD patients in the first half of this year."

Study Design and Safety

In the Phase I/IIa trial of RGX-314, 42 patients with severe wet AMD requiring frequent anti-vascular endothelial growth factor (anti-VEGF) injections were treated across five dose cohorts, with doses ranging from 3x109 GC/eye to 2.5x1011 GC/eye. Patients were enrolled into all dose cohorts independent of their neutralizing antibody titers to AAV and did not receive prophylactic immune suppressive oral corticosteroid therapy before or after administration of RGX-314.

Patients in the study are being assessed each month for 24 months and will receive safety follow-up for five years after RGX-314 administration. Efficacy assessments for the study include reduction in anti-VEGF intravitreal injections, change in vision as measured by Best Corrected Visual Acuity (BCVA), change in central retinal thickness (CRT) as measured by spectral domain optical coherence tomography (SD-OCT), and protein expression levels as measured from aqueous samples by electrochemiluminescence immunoassay (ECL).

As of April 6, 2020, RGX-314 continued to be well-tolerated across all cohorts, with no drug-related serious adverse events (SAEs) reported. Sixteen SAEs that were not related to RGX-314, including two ocular procedure-related SAEs, were reported in ten patients. There have been no reports of clinically-determined immune responses, drug-related ocular inflammation, or post-surgical inflammation beyond what is expected following routine vitrectomy.

Across all 42 patients in the study, the most common nonserious adverse events in the study eye were generally assessed as mild (90%). These included post-operative conjunctival hemorrhage (69% of patients), post-operative inflammation (36% of patients), eye irritation (17% of patients), eye pain (17% of patients), and post-operative visual acuity reduction (17% of patients). In 67% of patients across all cohorts, and in 83% of patients in Cohorts 3-5, mild to moderate retinal pigmentary changes were observed on imaging, the majority of which were in the peripheral inferior retina. There was no evidence of clinical symptoms or changes to visual acuity related to retinal pigmentary changes. Retinal hemorrhage was observed in 17% of patients and is an anticipated event in patients with severe wet AMD.

Summary of Long-term Data for Cohort 3 Over Two Years

Positive long-term potential efficacy signals were sustained over two years in Cohort 3.The mean change in visual acuity across all six patients in Cohort 3 was markedly improved over two years, with a mean BCVA improvement of +14 letters, and the mean change in CRT was stable, with an increase of +2 m.

Patients in Cohort 3 also demonstrated long-term reductions in anti-VEGF treatment burden over two years with a mean annualized rate of 2.8 anti-VEGF injections after administration of RGX-314, which is a reduction of over 60% from the mean annualized injection rate during the twelve months prior to administration of RGX-314. Three out of six (50%) patients received no anti-VEGF injections over two years following one-time administration of RGX-314. One patient received four anti-VEGF injections after RGX-314 administration and then did not receive anti-VEGF injections from nine months through two years.

The four patients who did not receive anti-VEGF injections after nine months demonstrated a mean BCVA improvement of +14 letters, with a range of +6 letters to +25 letters. In addition, these patients had stable retinal thickness with a mean change of +9 m.

Additionally, long-term intraocular RGX-314 protein expression was stable in patients in Cohort 3 over two years. The mean RGX-314 protein expression level in Cohort 3 was 227.2 ng/ml at two years, compared to 217.8 ng/ml at six months. The mean RGX-314 protein expression level in the four patients who did not receive anti-VEGF injections after nine months was 291.7 ng/ml at two years, compared to 273.6 ng/ml at six months.

Summary of Data for Cohorts 4 and 5

Consistent with previous results, intraocular RGX-314 protein expression levels increased in a dose-dependent manner across cohorts when measured at six months after administration of RGX-314; the mean protein expression level in Cohort 4 and Cohort 5 was 653.6 ng/ml and 848.7 ng/ml, respectively.

Patients in Cohort 5 continued to demonstrate a meaningful reduction in anti-VEGF treatment burden over nine months following administration of RGX-314, with 8/11 (73%) patients remaining anti-VEGF injection-free, and a reduction across the cohort of over 80% from the mean annualized injection rate during the 12 months prior to RGX-314 administration.

Conference Call

In connection with this announcement, REGENXBIO will host a webcast and conference call with accompanying slides today at 8:30 a.m. ET. This event will feature study investigators Allen C. Ho, M.D., Wills Eye Hospital and Mid Atlantic Retina, Robert Avery, M.D., Founder of California Retina Consultants and Research Foundation, and Peter Campochiaro, M.D., Johns Hopkins Wilmer Eye Institute.

To access a live or recorded webcast of the call and accompanying slides, please visit the "Investors" section of the REGENXBIO website at http://www.regenxbio.com. To access the live webcast by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 6668158. The recorded webcast will be available for approximately 30 days following the call.

About RGX-314

RGX-314 is being developed as a potential one-time treatment for wet AMD, diabetic retinopathy, and other additional chronic retinal conditions treated with anti-VEGF. RGX-314 consists of the NAV AAV8 vector encoding an antibody fragment which is designed to inhibit VEGF, modifying the pathway for formation of new leaky blood vessels which lead to retinal fluid accumulation and vision loss.

About the Phase I/IIa Clinical Trial of RGX-314

RGX314 is being evaluated in a Phase I/IIa, multi-center, open-label, multiple-cohort, doseescalation study in adult patients with wet AMD in the United States. The study includes patients previously treated for wet AMD who are responsive to anti-VEGF therapy. The study is designed to evaluate five escalating doses of RGX-314, with six patients in the first three dose cohorts and 12 patients in the fourth and fifth dose cohorts. Patients were enrolled into all dose cohorts independent of their neutralizing antibody titers to AAV and did not receive prophylactic immune suppressive oral corticosteroid therapy before or after administration of RGX-314. The primary endpoint of the study is safety at 6 months following administration of RGX-314. Secondary endpoints include visual acuity, retinal thickness on SDOCT, ocular RGX-314 protein expression, and the need for additional anti-VEGF therapy. Following completion of the primary study period, patients enter a follow-up period and will continue to be assessed until week 106 for long-term safety and durability of effect.

About Wet AMD

Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to 12 weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time.

AboutREGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Forward-Looking Statements

This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO's future operations and clinical trials. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, the impact of the COVID-19 pandemic or similar public health crises on REGENXBIO's business, and other factors, many of which are beyond the control of REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2019, and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the U.S. Securities and Exchange Commission (SEC) and are available on the SEC's website at http://www.sec.gov. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements,whether as a result of new information, future events or otherwise.

Contacts:

Tricia TruehartInvestor Relations and Corporate Communications347-926-7709ttruehart@regenxbio.com

Investors:Heather Savelle, 212-600-1902heather@argotpartners.com

Media:David Rosen, 212-600-1902david.rosen@argotpartners.com

Read this article:
REGENXBIO Announces Additional Positive Long-term and Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD - Herald-Mail Media

Recommendation and review posted by Bethany Smith

MILAN--(BUSINESS WIRE)--Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today an investment in Genespire, a Milan-based gene-therapy company developing best-in-class therapies for patients affected by genetic diseases. This is the third investment for the Sofinnova Telethon Fund, bringing the total financing of Italian startups by Sofinnova Partners to 25 million over the past six months. The Sofinnova Telethon Fund is the largest fund in Italy dedicated to biotechnologies, making early-stage investments in Italian companies targeting cures for rare and genetic diseases.

Genespire was spearheaded by the renowned gene therapy pioneer Professor Luigi Naldini. This investment by the Sofinnova Telethon Fund follows on the heels of its leading-edge investments in Epsilen Bio, which is developing a technology to turn off genes linked to specific pathologies without irreversibly modifying the DNA (a major potential safety advantage), and PinCell, a pre-clinical stage biotech company focused on the development of new therapies for rare dermatological diseases.

These investments are the result of the excellent collaboration between Sofinnova Partners and The Telethon Foundation, said Graziano Seghezzi, Managing Partner of Sofinnova Partners. These exceptional start-up companies validate our conviction in the strength of the Italian market for supporting biotechnological advances.

The Sofinnova Telethon Fund, managed by Sofinnova Partners, received commitments totaling 108 million, exceeding its target and establishing it as the largest fund to emerge from ITATech, a joint venture between the European Investment Fund (EIF) and Italys Cassa Depositi e Prestiti (CdP). We have gained unprecedented levels of support from Italian investors for our Italian biotech fund, added Mr. Seghezzi. We are proud and humbled by the trust we received from some of the countrys leading institutional, corporate and private investors who more than doubled the initial support provided by ITATech.

Francesca Pasinelli, CEO of The Telethon Foundation, said the biggest winners of this partnership would be the patients who suffer from rare and genetic diseases. This Fund has always been about them and additionally, is dedicated to elevating Italian science, supported by Italian investors and focused on Italys best entrepreneurs and companies, she said. We are seeing deep synergies between what we are doing with Sofinnova Partners and our ongoing, fruitful collaboration with the San Raffaele Hospital.

The Sofinnova Telethon Fund team is led by technology transfer specialists Lucia Faccio and Paola Pozzi, Partners at Sofinnova Partners, who are based in the Milan office. The office also houses BiovelocITA, Italys first biotechnology accelerator co-founded in 2015 by Sofinnova Partners in collaboration with Silvano Spinelli and Gabriella Camboni, two serial entrepreneurs with close ties to Sofinnova Partners. Ms. Faccio has over 20 years of experience in the domain as the Director of Research and Business Development of The Telethon Foundation and as the Director of the Technology Transfer Office at the San Raffaele Hospital. Ms. Pozzi, who succeeded Ms. Faccio at the San Raffaele Hospital, has 16 years of experience in patent portfolio market-oriented management and development leading to incorporation of new companies with strong IP assets.

The Sofinnova Telethon Fund will continue to invest exclusively in Italy, seeking to identify, create and develop some of the best companies in the field of rare and genetic diseases.

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over 2 billion under management. For more information, please visit: http://www.sofinnovapartners.com

About Genespire

Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini, Prof. Alessio Cantore, The Telethon Foundation and San Raffaele Hospital. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and backed by Sofinnova Partners.

About Epsilen Bio

Epsilen Bio is a biotechnology company developing transformative therapies for patients affected by underserved medical conditions, through stable and long-lasting epigenetic silencing of genes involved in pathological processes. Based in Milan, Italy, Epsilen Bio was founded in December 2019 by the renowned gene therapy experts Prof. Angelo Lombardo and Prof. Luigi Naldini, The Telethon Foundation and San Raffaele Hospital. Epsilen Bio is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute, and received seed funding from Sofinnova Partners. For more information, please visit: http://www.epsilenbio.com

About PinCell

PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapy for the treatment of rare, severe skin diseases with high unmet medical need. Based in Milan, Italy, PinCell was founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia by the world-class dermatology experts Prof. Carlo Pincelli and Dr. Alessandra Marconi. PinCell received seed funding from Sofinnova Partners. For more information, please visit: http://www.pincell.it

About The Telethon Foundation (Fondazione Telethon)

The Fondazione Telethon is a non-profit organisation created in 1990 as a response to the appeals of a group of stakeholders, who saw scientific research as the only real opportunity to fight genetic diseases and win. Thanks to the funds raised through the television marathon, along with other initiatives and a network of partners and volunteers, Telethon finances the best scientific research on rare genetic diseases, with the ultimate objective of making the treatments developed available to everyone who needs them. Throughout its 28 years of activity, Fondazione Telethon has invested more than 528 million in funding more than 2.630 projects to study more than 570 diseases, involving over 1.600 scientists. Fondazione Telethon has made a significant contribution to the worldwide advancement of knowledge regarding rare genetic diseases and of research with a view to developing treatments. For more information, please visit: http://www.telethon.it

About San Raffaele Hospital (Ospedale San Raffaele)

Ospedale San Raffaele (OSR) is a clinical-research-university hospital established in 1971 to provide international-level specialised care for the most complex and difficult health conditions. OSR is part of Gruppo San Donato, the leading hospital group in Italy. The hospital is a multi-specialty center with over 60 clinical specialties; it is accredited by the Italian National Health System to provide care to both public and private, national and international patients. Research at OSR focuses on integrating basic, translational and clinical activities to provide the most advanced care to our patients. The institute is recognized as a global authority in molecular medicine and gene therapy, and is at the forefront of research in many other fields. Ospedale San Raffaele is a first-class institute which treats many diseases and stands out for the deep interaction between clinical and scientific area. This makes the transfer of scientific results from the laboratories to the patients bed easier. Its mission is to improve knowledge of diseases, identify new therapies and encourage young scientists and doctors to grow professionally. For more information, please visit: http://www.hsr.it

Excerpt from:
Sofinnova Partners Announces Third Investment From Its Italian Fund - Business Wire

Recommendation and review posted by Bethany Smith

How do we learn when to cooperate, and when to cheat? It likely depends in part on the social interactions we observe growing up. Turns out that the same is true for cleaner fish (Labroides dimidiatus), according to a recent study.

Cleaner fish, also known as bluestreak cleaner wrasse, feed on ectoparasites found on other fishes their clients. What cleaner fish really like to eat, however, is the protective mucus that covers their clients bodies. While eating ectoparasites is great for client fishes, cheating by eating mucus is bad. Client fishes will punish cheaters by fleeing, or by chasing the cheaters around.

Photo by David Clode on Unsplash

Whats the best option, to cheat and eat a brief but delicious snack (and risk being chased around), or to cooperate and eat a larger, peaceful, but not as tasty meal? A group of researchers led by Noa Truskanov, from the University of Neuchtel, set out to understand how juvenile cleaner fish learn to answer that question.

In a series of experiments recently published in Nature Communications, Truskanov and her collaborators allowed juvenile cleaner fish to observe adults interacting with model clients. They then placed these juveniles in the same situations they had just observed, and tested if they copied the adult fish, learned from the adult fish, or behaved independently of what they had just seen.

Their results show that juvenile fish are actively learning to cooperate by observing the interactions of adult fish with their clients. Juvenile fish are more cooperative when client fishes are intolerant of cheating. When given the choice, however, they prefer clients who allow them to cheat a little. Juvenile fish also didnt just imitate random adult preferences, showing that there are not copying, but rather learning.

Although both social learning and cooperation are widespread in nature, examples of animals that learn socially how to cooperate are extremely scarce. This leads us, humans, to erroneously assume that we are the only ones who learn to cooperate by observing others. Cleaner fish are putting us right back in our place: they can do it, too.

Link:
A real world version of Pokmon Go lets you track orangutans in the jungle - Massive Science

Recommendation and review posted by Bethany Smith

Add a new, 100 million California facility to the growing gene therapy infrastructure.

Merck KGaA announced they are opening a second gene therapy and viral vector factory in Carlsbad, California. The new center will be just one point in the global supply chain Big Pharma is rapidly erecting to keep manufacturing capacity for the new technology at pace with clinical development. Over the past year, Novartis, PTC Therapeutics, Pfizer and Vertex each announced or opened new facilities in Switzerland, North Carolina and New Jersey that will help build gene therapy.

In November,Reutersreported that 11 drugmakers had set aside $2 billion for the manufacturing effort. They were led by Novartis, the giant behind the second FDA-approved gene therapy in Zolgensma which planned to spend $500 million, and Pfizer, which has yet to get a gene therapy approved but will spend $600 million. Catalent and Thermo Fisher, meanwhile, each spent over a billion dollars acquiring companies involved in gene therapy or viral vector manufacturing.

Merck KGaA last shored up its gene therapy manufacturing in 2016 the year before the first gene therapy was approved in the US when they expanded their original Carlsbad facility from 44,000 to 65,000 feet. At 140,000 feet, the new facility will be more than double the size of its older neighbor. Gene therapies and the viral vectors used to deliver them will be cooked up in 1,000 liter bioreactors metal vats roughly the size of 260 gallons of milk. Merck has not said when it is scheduled for completion.

Although Merck KGaA lists no gene therapies in its most recent pipeline, the German drugmaker uses its facilities to help biotechs focused on the emerging modality to manufacture their products. The list of approved gene therapies can still be counted on one hand, but hundreds are now in clinical trials.

Manufacturing emerged as a pressing bottleneck almost as soon as Spark Therapeutics got Luxturna, a treatment for a form of inherited blindness, approved as the US first gene therapy. In an op-ed in STAT last year, Sparks head of technical operations, Diane Blumenthal, described the process of building in Philadelphia one of the first in-house gene therapy manufacturing facilities. With regulators increasingly open to approving the treatments quickly, she encouraged other companies to invest in manufacturing in advance of even knowing if the therapy works, particularly because gene therapy requires customization in ways few other modalities do.

And she warned the problem will only get more pressing.

There isnt a gene therapy manufacturing playbook yet to guide the development of gene therapies, Blumenthal wrote. Manufacturing a gene therapy is only half the battle. The other half is making enough of it, doing that as efficiently as possible, and getting it to the patients who need it. These challenges become even more urgent to tackle as the industry shifts to the next chapter in gene therapy development, from treatments made in small batches for small patient populations to bigger volumes for larger rare-disease populations and commercial scale.

Read the original here:
Merck KGaA adds to gene therapy manufacturing boom with 100M facility in California - Endpoints News

Recommendation and review posted by Bethany Smith

The report entitled Gene Therapy Market: Global Industry Analysis 2020-2026is a comprehensive research study presenting significant data By Reportspedia.com

Global Gene Therapy Market 2020 Industry Research Report offers you market size, industry growth, share, investment plans and strategies, development trends, business idea and forecasts to 2026. The report highlights the exhaustive study of the major market along with present and forecast market scenario with useful business decisions.

Gene Therapy business report includes primary research together with the all-inclusive investigation of subjective as well as quantitative perspectives by different industry specialists, key supposition pioneers to gain a more profound understanding of the industry execution.[Request The COVID 19 Impact On This Market]. The report gives the sensible picture of the current industrial situation which incorporates authentic and anticipated market estimate in terms of value and volume, technological advancement, macroeconomic and governing factors in the market.

Top Key Manufacturers of Gene Therapy industry Report:-

Sibiono GeneTech,Advantagene,Spark Therapeutics,Shanghai Sunway Biotech Co. LtdBluebird Bio,UniQure NVAvalanche Bio,Celladon,Sangamo,Dimension Therapeutics

For Better Insights Go With This Free Sample Report Enabled With Respective Tables and Figures: https://www.reportspedia.com/report/life-sciences/global-gene-therapy-market-research-report-2014-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/44997 #request_sample

Gene Therapy Market segment by Type-

Viral vectorNon-viral vector

Gene Therapy Market segment by Application-

Oncological DisordersRare DiseasesCardiovascular DiseasesNeurological DisordersInfectious diseaseOther Diseases

(***Our FREE SAMPLE COPY of the report gives a brief introduction to the research report outlook, TOC, list of tables and figures, an outlook to key players of the market and comprising key regions.***)

The report offers a multi-step view of the Global Gene Therapy Market. The first approach focuses through an impression of the market. This passage includes several definitions, arrangements, the chain assembly of the industry in one piece, and various segmentation on the basis ofsolution, product and regionalong with different geographic regions for the global market. This part of the section also integrates an all-inclusive analysis of the different government strategies and enlargement plans that influence the market, its cost assemblies and industrialized processes. The second subdivision of the report includes analytics on the Global Gene Therapy Market based on its revenue size in terms of value and volume.

Gene Therapy Market Segmentation Analysis:-

Global Gene Therapy market segmentation, by solution: Biological, Chemical, Mechanical, Global Gene Therapy market segmentation, by product: Stress Protection, Scarification, Pest Protection

Gene Therapy Market Regional Analysis:-North America(United States, Canada),Europe(Germany, Spain, France, UK, Russia, and Italy),Asia-Pacific(China, Japan, India, Australia, and South Korea),Latin America(Brazil, Mexico, etc.),The Middle East and Africa(GCC and South Africa).

We have designed the Gene Therapy report with a group of graphical representations, tables, and figures which portray a detailed picture of Gene Therapy industry. In addition, the report has a clear objective to mark probable shareholders of the company. Highlighting business chain framework explicitly offers an executive summary of market evolution. Thus it becomes easy to figure out the obstacles and uplifting profit stats. In accordance with a competitive prospect, this Gene Therapy report dispenses a broad array of features essential for measuring the current Gene Therapy market performance along with technological advancements, business abstract, strengths and weaknesses of market position and hurdles crossed by the leading Gene Therapy market players to gain leading position.

For more actionable insights into the competitive landscape of global Gene Therapy market, get a customized report here: https://www.reportspedia.com/report/life-sciences/global-gene-therapy-market-research-report-2014-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/44997 #inquiry_before_buying

Some Notable Report Offerings:

Report Table of Content Overview Gives Exact Idea About International Gene Therapy Market Report:

Chapter 1 describes Gene Therapy report important market inspection, product cost structure, and analysis, Gene Therapy market size and scope forecast from 2017 to 2026. Although, Gene Therapy market gesture, factors affecting the expansion of business also deep study of arise and existing market holders.

Chapter 2 display top manufacturers of Gene Therapy market with sales and revenue and market share. Furthermore, report analyses the import and export scenario of industry, demand and supply ratio, labor cost, raw material supply, production cost, marketing sources, and downstream consumers of market.

Chapter 3, 4, 5 analyses Gene Therapy report competitive analysis based on product type, their region wise depletion and import/export analysis, the composite annual growth rate of market and foretell study from 2017 to 2026.

Chapter 6 gives an in-depth study of Gene Therapy business channels, market sponsors, vendors, dispensers, merchants, market openings and risk.

Chapter 7 gives Gene Therapy market Research Discoveries and Conclusion

Chapter 8 gives Gene Therapy Appendix

To Analyze Details Of Table Of Content (TOC) of Gene Therapy Market Report, Visit Here: https://www.reportspedia.com/report/life-sciences/global-gene-therapy-market-research-report-2014-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/44997 #table_of_contents

Originally posted here:
Global Gene Therapy Market Analysis, Technologies, Innovations, Future Guidelines and Forecasts Report 2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

Nancy J. Hutson, Ph.D.

Nancy J. Hutson, Ph.D. has been appointed to Clearside Biomedical's Board of Directors, effective April 21, 2020.

ALPHARETTA, Ga., April 22, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Nancy J. Hutson, Ph.D. has been appointed to the Company's Board of Directors, effective April 21, 2020.

The addition of Nancy Hutson to our Board of Directors comes at a key time as we are expanding our research and development pipeline and preparing to initiate a clinical program targeting the treatment of wet age-related macular degeneration with CLS-AX, said William Humphries, Chairman of the Clearside Board of Directors. Nancy brings a deep understanding of the business coupled with an in-depth knowledge of research, drug development and dynamic business situations from her years of R&D leadership at Pfizer and extensive board service in a number of biopharmaceutical companies. We welcome Nancy and look forward to making further progress in achieving our strategic goals.

I look forward to working with the Clearside team to leverage the Companys proprietary suprachoroidal space injection platform, said Dr. Hutson. With a flexible treatment approach, unique R&D pipeline, multiple global partnerships, and a robust patent portfolio, Clearside has a compelling opportunity to make a difference for patients with back of the eye diseases and deliver value for shareholders.

Nancy J. Hutson, Ph.D., is a highly accomplished healthcare executive with more than 30 years of experience as a seasoned research and development expert and leader within the biopharmaceutical industry. Dr. Hutson retired from Pfizer, Inc. in 2006 after spending 25 years in various research and leadership positions, serving as Senior Vice President, Pfizer Global Research and Development and Director of Pfizer's pharmaceutical R&D site, known as Groton/New London Laboratories. At Pfizer, she led 4,500 colleagues and managed a budget in excess of $1 billion. Dr. Hutson is currently a board member of Endo International, plc (ENDP), BioCryst Pharmaceuticals, Inc. (BCRX) and PhaseBio Pharmaceuticals, Inc (PHAS). She serves as Vice-Chair of the Board of Trustees at Illinois Wesleyan University. Dr. Hutson holds a Bachelor of Arts degree from Illinois Wesleyan University and a Ph.D. degree from Vanderbilt University. She completed a Postdoctoral fellowship in Biochemistry at University of Oxford.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearsides proprietary SCS Microinjector targeting the suprachoroidal space (SCS) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Companys SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit http://www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin Remy Bernarda ir@clearsidebio.com(678) 430-8206

Source: Clearside Biomedical, Inc.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/27843a49-a1c9-4e2f-a571-ff96a1a56ae3

The rest is here:
Clearside Biomedical Appoints Nancy J. Hutson, Ph.D. to its Board of Directors - GlobeNewswire

Recommendation and review posted by Bethany Smith

Bluebird Bio

Global Gene Therapy For CNS Disorders Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=175792&utm_source=COD&utm_medium=888

Global Gene Therapy For CNS Disorders Market Regions and Countries Level Analysis

The regional analysis is a very complete part of this report. This segmentation highlights Gene Therapy For CNS Disorders sales at regional and national levels. This data provides a detailed and accurate analysis of volume by country and an analysis of market size by region of the world market.

The report provides an in-depth assessment of growth and other aspects of the market in key countries such as the United States, Canada, Mexico, Germany, France, the United Kingdom, Russia and the United States Italy, China, Japan, South Korea, India, Australia, Brazil and Saudi Arabia. The chapter on the competitive landscape of the global market report contains important information on market participants such as business overview, total sales (financial data), market potential, global presence, Gene Therapy For CNS Disorders sales and earnings, market share, prices, production locations and facilities, products offered and applied strategies. This study provides Gene Therapy For CNS Disorders sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Why choose us:

We offer state of the art critical reports with accurate information about the future of the market.

Our reports have been evaluated by some industry experts in the market, which makes them beneficial for the company to maximize their return on investment.

We provide a full graphical representation of information, strategic recommendations and analysis tool results to provide a sophisticated landscape and highlight key market players. This detailed market assessment will help the company increase its efficiency.

The dynamics of supply and demand shown in the report offer a 360-degree view of the market.

Our report helps readers decipher the current and future constraints of the Gene Therapy For CNS Disorders market and formulate optimal business strategies to maximize market growth.

Have Any Query? Ask Our Expert @ https://www.marketresearchintellect.com/need-customization/?rid=175792&utm_source=COD&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Gene Therapy For CNS Disorders market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Gene Therapy For CNS Disorders market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Gene Therapy For CNS Disorders Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Gene Therapy For CNS Disorders Market Size, Gene Therapy For CNS Disorders Market Growth, Gene Therapy For CNS Disorders Market Forecast, Gene Therapy For CNS Disorders Market Analysis

Excerpt from:
Gene Therapy For CNS Disorders Market Analysis by Size, Share, Top Key Manufacturers, Demand Overview, Regional Outlook And Growth Forecast to 2026 -...

Recommendation and review posted by Bethany Smith

Grand View Research, Inc. Market Research And Consulting

According to report published by Grand View Research, The global advanced therapy medicinal products market size was valued at USD 3.14 billion in 2019 and is projected to expand at a CAGR of 17.4% during the forecast period

The globaladvanced therapy medicinal products marketsize is expected to reach USD 9.6 billion by 2026, expanding at a CAGR of 17.4% over the forecast period, according to a new report published by Grand View Research, Inc. The use of advanced therapy medicinal products (ATMPs) is well-proven for the improvement in the quality of life and health status in the long run for patients suffering from life-threatening conditions. This is particularly for diseases with few or no alternative treatment options. These novel treatment modes deliver transformative advantages not offered by conventional forms of disease treatment, thereby driving the ATMP market.

In the current scenario, ATMPs are expensive for patients as well as health insurance schemes. Growing competition to gain revenue share could help reduce prices and improve the affordability, along with the acceptance of these products as mainstream medicine. Furthermore, manufacturers are embracing efforts to streamline technology and logistics for the provision of therapies at accessible prices.

Request a sample Copy of the Global Advanced Therapy Medicinal Products Market Research Report @ http://www.grandviewresearch.com/industry-analysis/advanced-therapy-medicinal-products-market/request/rs1

Moreover, lack of manufacturing capabilities to meet growing consumer demand coupled with the resource and budget constraints faced by advanced therapy medicinal product developers has created lucrative avenues for contract services providers and has intensified the market competition. This has led to a rise in market activities by contract service providers. For instance, in November 2019, Fujifilm Diosynth established a 60,000-square-feet Gene Therapy Innovation Center to offer downstream, upstream, and analytical services.

Further key findings from the report suggest:

Have Any Query? Ask Our Experts @www.grandviewresearch.com/inquiry/7111/ibb

Grand View Research has segmented the global advanced therapy medicinal products market on the basis of therapy type and region:

Advanced Therapy Medicinal ProductsTherapy Type Outlook (Revenue, USD Million, 2015 2026)

Advanced Therapy Medicinal ProductsRegional Outlook (Revenue, USD Million, 2015 2026)

Browse Related Category @

Nuclear Medicine Market http://www.grandviewresearch.com/industry-analysis/nuclear-medicines-market

Aromatherapy Carrier Oil Market http://www.grandviewresearch.com/industry-analysis/aromatherapy-carrier-oil-market

About Grand View Research

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research Guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

Media ContactCompany Name: Grand View Research, Inc.Contact Person: Sherry James, Corporate Sales Specialist U.S.A.Email: Send EmailPhone: 1-415-349-0058, Toll Free: 1-888-202-9519Address: 201, Spear Street, 1100 City: San FranciscoState: CaliforniaCountry: United StatesWebsite: https://www.grandviewresearch.com/industry-analysis/advanced-therapy-medicinal-products-market

Read more:
Advanced Therapy Medicinal Products Market to Reach $9.6 Billion by 2026 | Key Players Spark Therapeutics, Inc.; Bluebird Bio, Inc.; Novartis AG;...

Recommendation and review posted by Bethany Smith

SENVEST MANAGEMENT LLC bought a fresh place in At Home Group Inc. (NYSE:HOME). The institutional investor bought 3.8 million shares of the stock in a transaction took place on 3/02/2020. In another most recent transaction, which held on 3/17/2020, CAS INVESTMENT PARTNERS LLC bought approximately 1.6 million shares of At Home Group Inc. In a separate transaction which took place on 3/31/2020, the institutional investor, NISA INVESTMENT ADVISORS LLC bought 11.6 thousand shares of the companys stock.

In the most recent purchasing and selling session, At Home Group Inc. (HOME)s share price decreased by -3.06 percent to ratify at $1.90. A sum of 1441416 shares traded at recent session and its average exchanging volume remained at 2.62M shares. The 52-week price high and low points are important variables to concentrate on when assessing the current and prospective worth of a stock. At Home Group Inc. (HOME) shares are taking a pay cut of -92.34% from the high point of 52 weeks and flying high of 58.33% from the low figure of 52 weeks.

At Home Group Inc. (HOME) shares reached a high of $1.985 and dropped to a low of $1.75 until finishing in the latest session at $1.90. Traders and investors may also choose to study the ATR or Average True Range when concentrating on technical inventory assessment. Currently at 0.43 is the 14-day ATR for At Home Group Inc. (HOME). The highest level of 52-weeks price has $24.81 and $1.20 for 52 weeks lowest level. After the recent changes in the price, the firm captured the enterprise value of $1.95B. The liquidity ratios which the firm has won as a quick ratio of 0.10, a current ratio of 0.80 and a debt-to-equity ratio of 0.78.

Having a look at past record, were going to look at various forwards or backwards shifting developments regarding HOME. The firms shares fell -2.06 percent in the past five business days and shrunk -6.86 percent in the past thirty business days. In the previous quarter, the stock fell -68.39 percent at some point. The output of the stock decreased -80.90 percent within the six-month closing period, while general annual output lost -91.77 percent. The companys performance is now negative at -65.45% from the beginning of the calendar year.

According to WSJ, At Home Group Inc. (HOME) obtained an estimated Hold proposal from the 9 brokerage firms currently keeping a deep eye on the stock performance as compares to its rivals. 0 equity research analysts rated the shares with a selling strategy, 8 gave a hold approach, 0 gave a purchase tip, 0 gave the firm a overweight advice and 1 put the stock under the underweight category. The average price goal of one year between several banks and credit unions that last year discussed the stock is $2.76.

CRISPR Therapeutics AG (CRSP) shares on Mondays trading session, jumped 3.97 percent to see the stock exchange hands at $53.46 per unit. Lets a quick look at companys past reported and future predictions of growth using the EPS Growth. EPS growth is a percentage change in standardized earnings per share over the trailing-twelve-month period to the current year-end. The company posted a value of $0.97 as earning-per-share over the last full year, while a chance, will post -$4.96 for the coming year. The current EPS Growth rate for the company during the year is 134.10% and predicted to reach at -10.00% for the coming year. In-depth, if we analyze for the long-term EPS Growth, the out-come was 54.00% for the past five years.

The last trading period has seen CRISPR Therapeutics AG (CRSP) move -27.76% and 65.51% from the stocks 52-week high and 52-week low prices respectively. The daily trading volume for CRISPR Therapeutics AG (NASDAQ:CRSP) over the last session is 1.08 million shares. CRSP has attracted considerable attention from traders and investors, a scenario that has seen its volume jump 6.1% compared to the previous one.

Investors focus on the profitability proportions of the company that how the company performs at profitability side. Return on equity ratio or ROE is a significant indicator for prospective investors as they would like to see just how effectively a business is using their cash to produce net earnings. As a return on equity, CRISPR Therapeutics AG (NASDAQ:CRSP) produces 11.70%. Because it would be easy and highly flexible, ROI measurement is among the most popular investment ratios. Executives could use it to evaluate the levels of performance on acquisitions of capital equipment whereas investors can determine that how the stock investment is better. The ROI entry for CRSPs scenario is at 4.90%. Another main metric of a profitability ratio is the return on assets ratio or ROA that analyses how effectively a business can handle its assets to generate earnings over a duration of time. CRISPR Therapeutics AG (CRSP) generated 9.60% ROA for the trading twelve-month.

Volatility is just a proportion of the anticipated day by day value extendthe range where an informal investor works. Greater instability implies more noteworthy benefit or misfortune. After an ongoing check, CRISPR Therapeutics AG (CRSP) stock is found to be 5.84% volatile for the week, while 7.59% volatility is recorded for the month. The outstanding shares have been calculated 59.15M. Based on a recent bid, its distance from 20 days simple moving average is 22.91%, and its distance from 50 days simple moving average is 13.27% while it has a distance of 4.89% from the 200 days simple moving average.

The Williams Percent Range or Williams %R is a well-known specialized pointer made by Larry Williams to help recognize overbought and oversold circumstances. CRISPR Therapeutics AG (NASDAQ:CRSP)s Williams Percent Range or Williams %R at the time of writing to be seated at 15.52% for 9-Day. It is also calculated for different time spans. Currently for this organization, Williams %R is stood at 14.52% for 14-Day, 13.69% for 20-Day, 26.55% for 50-Day and to be seated 43.87% for 100-Day. Relative Strength Index, or RSI(14), which is a technical analysis gauge, also used to measure momentum on a scale of zero to 100 for overbought and oversold. In the case of CRISPR Therapeutics AG, the RSI reading has hit 65.53 for 14-Day.

Visit link:
Growth May Be Waiting: At Home Group Inc. (HOME) and CRISPR Therapeutics AG (CRSP) - BOV News

Recommendation and review posted by Bethany Smith

Humanity is currently facing a huge challenge imposed by the coronavirus. Borders are being shut down, planes grounded, and factories closed. At the same time, scientists and public health professionals are working on tests, treatments, and vaccines to soon provide a medical response. Coping with corona might be one of the largest tests humans have faced in the past decades but it wont be the last virus we need to defeat. It is time to embrace bioscience and allow more research and applications of genetic alteration methods.

For the layman, all this technobabble about mutagenesis and genetic engineering is difficult to comprehend and it took me personally a good amount of reading to start grasping what different methods exist and how these can massively improve our quality of life.

Lets first look at the four most common ways to alter the genes of a plant or animal:

This can be even done in grown humans that are alive, which is a blessing for everyone who suffers from genetic disorders. We are able to repair genes in live organisms. Gene editing is also thousands of times more accurate than just bombarding seeds with radiation. Some applied examples are deactivating the gene responsible for generating gluten in wheat: The result is gluten-free wheat. There are several methods that achieve this. One of the most popular ones these days is the so-called CRISPR Cas-9. These scissors are usually reprogrammed bacteria that transmit the new gene information or deactivate defunct or unwanted genes. Many science fiction novels and movies show a future in which we can deactivate genetic defects and cure humans from terrible diseases. Some examples of stories in which CRISPR-like techniques have been used are movies such as GATTACA, Star Treks Wrath of Khan, or the Expanse series in which gene editing plays a crucial role in growing crops in space.

Synthetic biologists have started usingCRISPR to synthetically create partsof the coronavirus in an attempt to launch a vaccine against this lung disease and be able to mass-produce it very quickly. In combination with computer simulations and artificial intelligence, the best design for such a vaccine is calculated on a computer and then synthetically created. This speeds up vaccine development and cuts it from years to merely months. Regulators and approval bodies have shown that in times of crisis they can also rapidly approve new testing and vaccination procedures which usually require years of back and forth with agencies such as the FDA?

CRISPR also allows the search for specific genes, also genes of a virus. This helped researchersto build fast and simple testing proceduresto test patients for corona.

In the long term, gene editing might allow us to increase the immunity of humans by altering our genes and making us more resistant to viruses and bacteria.

While the coronavirus seems to really test our modern society, we also need to be aware that this wont be the last pathogen that has the potential to kill millions. If we are unlucky, corona might mutate quickly and become harder to fight. The next dangerous virus, fungus, or bacteria is probably around the corner. Hence we need to embrace the latest inventions of biotechnology and not block genetic research and the deployment of its findings.

Right now a lot of red tape and even outright bans are standing between lifesaving innovations such as CRISPR and patients around the world. We need to rethink our hostility towards genetic engineering and embrace it. To be frank: We are in a constant struggle to fight newly occurring diseases and need to be able to deploy state of the art human answers to this.

Fred Roeder is a Health Economist from Germany and has worked in healthcare reform in North America, Europe, and several former Soviet Republics. One of his passions is to analyze how disruptive industries and technologies allow consumers more choice at a lower cost. Follow him on Twitter @FredCyrusRoeder

A version of this article was originally published at Consumer Choice Center and has been republished here with permission. The center can be found on Twitter @ConsumerChoiceC

Read more from the original source:
What comic book super heroes and villains tell us about plant and human gene editing and the coronavirus - Genetic Literacy Project

Recommendation and review posted by Bethany Smith

Researchers say they've developed a low-cost swab test that can diagnose Covid-19 infections in about 45 minutes.

The CRISPR-based test which uses gene-targeting technology and requires no specialised equipment could help relieve testing backlogs in the United States as Covid-19 continues to spread, the scientists said.

The US Food and Drug Administration has not approved the test, but clinical assessments are being conducted in an effort to fast-track approval. The test is described in a paper published on 16 April in the journal Nature Biotechnology.

"The introduction and availability of CRISPR technology will accelerate deployment of the next generation of tests to diagnose Covid-19 infection," co-lead developer Dr Charles Chiu said in a University of California, San Francisco news release. He is a professor of laboratory medicine at the university.

The new test dubbed SARS-CoV-2 DETECTR is among the first to use CRISPR gene-targeting technology to test for the presence of the novel coronavirus.

CRISPR can be modified to target any genetic sequence, so test developers "programmed" it to zero in on two sequences in the genome of SARS-CoV-2, which causes Covid-19.

One sequence is common to all SARS-like coronaviruses, while the other is unique to SARS-CoV-2. Checking for both sequences ensures that the new test can distinguish between SARS-CoV-2 and closely related viruses, Chiu and his team explained.

Like other tests, this one can detect coronavirus in samples from respiratory swabs from patients. It provides results in about 45 minutes, compared with roughly four hours for widely used tests based on polymerase chain reaction (PCR) techniques.

The researchers said that another advantage of the new test is that it can be performed in virtually any lab, using off-the-shelf chemical agents and common equipment. PCR-based tests require specialised equipment, limiting them to well-equipped diagnostic labs.

The new test is also easy to interpret. Much like a store-bought pregnancy test, dark lines appear on test strips to indicate the presence of coronavirus genes.

While the new test is slightly less sensitive than PCR-based tests, researchers said that's unlikely to have much impact in diagnosis because infected patients typically have high viral loads.

As they work to validate the new test for FDA approval, researchers are making tweaks so that it can be used in field testing at locations such as airports, schools and small clinics.

READ MORE | Physical distancing might need to be practised intermittently until 2022 - study

READ MORE | Coronavirus: The chloroquine debate: Two experts weigh in

READ MORE | Could a measles vaccine help in the fight against Covid-19?

See original here:
New Covid-19 test could give results in under an hour - but it's yet to be approved - Health24

Recommendation and review posted by Bethany Smith

A satellite that was ready for retirement has been given a new lease of life after being serviced in orbit by another satellite containing enough fuel to get it back up and running, the first time such a feat has been achieved.

The Northrop-Grumman satellite MEV-1 (Mission Extension Vehicle) docked with communications satellite Intelsat 901 and is now serving as its engine.

Intelsat 901 (pictured below) had almost run out of fuel and been shifted into a so called 'graveyard orbit' to prepare for the end of its useful life.

MEV-1 will now use its own thrusters and fuel supply to extend the satellites lifespan by performing station-keeping manoeuvres. It should be able to extend the useful lifespan of Intelsat 901 by up to five years before undocking and moving on to the next client satellite.

On average, there are about 20 satellites each year that expend all their fuel and must be retired.

Our MEV is a multi-use vehicle, said Joe Anderson of Northrop Grummans satellite servicing operations unit. It has a 15-year design life, but theres much more than 15 years of life extension fuel in the vehicle. This will allow us to service satellites in inclined orbits too.

MEV-1 launched on October 9 last year, it is the first life-extension vehicle and is under a contract with Intelsat, the worlds largest commercial satellite operator.

Once launched, MEV-1 raised its orbit to rendezvous with Intelsat 901 in geosynchronous equatorial orbit (GEO).

This process took three and a half months from launch and used both chemical and electric propulsion systems.

The two satellites initially docked in a graveyard orbit, which is situated approximately 180 miles above GEO and more than 22,000 miles above Earth, as a precautionary measure.

A few weeks after the MEV-1 launch, Intelsat 901 began to raise its own orbit from GEO to the graveyard, where the two vehicles rendezvoused and finally docked in late February 2020, moving at a rate of approximately 7,000 miles per hour while successfully aligning. Future MEV dockings are planned to take place directly in GEO. Intelsat 901 was returned to full service on April 2.

Currently, MEV-1s docking method takes advantage of a liquid apogee engine (LAE), which is present on around 80 per cent of GEO satellites, all bearing similar designs.

The LAE is normally used to finalise a craft's orbit at the start of its life but is never used again.

MEV-1 is able to capture and dock by inserting itself into the cone of the LAE to capture the client satellite.

Once captured, the mechanism retracts and the MEVs stanchions make firm contact with the client vehicles launch adapter ring ensuring a secure docking.

The docking procedure is purely mechanical at the moment, thereby avoiding the complications of fluid transfers and electrical or data connections.

In March, the US Space Force underwent its first satellite launch to bolster its constellation providing secure military communications.

Sign up to the E&T News e-mail to get great stories like this delivered to your inbox every day.

Continued here:
One satellite services another in orbit for the first time - E&T Magazine

Recommendation and review posted by Bethany Smith

Air Products and Chemicals, Inc. APD is slated to release second-quarter fiscal 2020 results ahead of the bell on Apr 23. The company is likely to have gained from new projects and productivity initiatives in the quarter. However, the impacts of higher maintenance spending are expected to get reflected on its results.

The industrial gases giant delivered a positive earnings surprise of around 2.9% in the last reported quarter. Sales also beat expectations as higher volumes and prices more than offset unfavorable currency swings and the impacts of contract modification in India and lower energy cost pass-through.

The companys shares have gained 9% in the past year against the industrys 38.3% decline.

Lets see how things are shaping up for this announcement.

What do the Estimates Say?

Air Products expects adjusted earnings per share for the fiscal second quarter in the band of $2.10-$2.20, which indicates a 9-15% rise year over year.

The Zacks Consensus Estimate for Air Products fiscal second quarter revenues is currently pegged at $2,143 million, suggesting a decline of 2.1% year over year.

The Zacks Consensus Estimate for revenues for the Industrial Gases Americas segment is currently pegged at $935 million, calling for a decline of 5.7% year over year. The consensus mark for the segments operating income stands at $257 million, essentially flat year over year.

The Zacks Consensus Estimate for revenues in the Industrial Gases Asia segment is pegged at $667 million, which suggests 6.7% year-over-year growth. The consensus mark for operating income for the segment is projected at $218 million, reflecting a year-over-year increase of 9%.

The Zacks Consensus Estimate for revenues in the Industrial Gases EMEA segment stands at $498 million, indicating a 0.8% year-over-year rise. The Zacks Consensus Estimate for operating income is pegged at $124 million, flat year over year.

The consensus mark for revenues for the Industrial Gases Global segment is pegged at $61 million, which indicates a rise of 13% year over year. The same for the segments operating income stands at a loss of $0.67 million.

Some Factors at Play

Air Products productivity actions, investments in high-return projects and benefits of acquisitions are expected to get reflected on fiscal second-quarter results. New projects are likely to have contributed to its volume growth.

The company remains committed to boost productivity to improve cost structure. It is seeing a positive impact of its productivity actions. Benefits from additional productivity and cost improvement programs are likely to have supported margins in the to-be-reported quarter.

Air Products also has been benefiting from higher pricing over the past several quarters and the same is expected to have continued in the fiscal second quarter.

However, the company is likely to have faced headwinds from higher maintenance spending in the fiscal second quarter, stemming from life extension work on certain facilities. Higher costs are likely to have affected margins in its Industrial Gases Americas segment.

Moreover, the companys Industrial Gases Asia segment is likely to have faced some headwinds in the fiscal second quarter from the Chinese Lunar New Year holiday which was extended by Beijing to contain the outbreak of coronavirus. The impacts of slowdown due to the Chinese New Year are expected to get reflected on sales and margins in Air Products Asia business.

Story continues

Air Products and Chemicals, Inc. Price and EPS Surprise

Air Products and Chemicals, Inc. Price and EPS Surprise

Air Products and Chemicals, Inc. price-eps-surprise | Air Products and Chemicals, Inc. Quote

What the Zacks Model Says

Our proven model doesnt conclusively predict an earnings beat for Air Products this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But thats not the case here.

Earnings ESP: Earnings ESP for Air Products is -4.83%. The Zacks Consensus Estimate for the fiscal second quarter currently stands at $2.07. You can uncover the best stocks to buy or sell before theyre reported with our Earnings ESP Filter.

Zacks Rank: Air Products currently carries a Zacks Rank #4 (Sell).

Stocks Poised to Beat Estimates

Here are some companies in the basic materials space you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:

Verso Corporation VRS, expected to release earnings on May 13, has an Earnings ESP of +20% and carries a Zacks Rank #1. You can see the complete list of todays Zacks #1 Rank stocks here.

Barrick Gold Corporation GOLD, scheduled to release earnings on May 6, has an Earnings ESP of +2.42% and carries a Zacks Rank #2.

Pretium Resources Inc. PVG, expected to release earnings on May 7, has an Earnings ESP of +25.81% and carries a Zacks Rank #2.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportPretium Resources, Inc. (PVG) : Free Stock Analysis ReportAir Products and Chemicals, Inc. (APD) : Free Stock Analysis ReportBarrick Gold Corporation (GOLD) : Free Stock Analysis ReportVerso Corporation (VRS) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Go here to see the original:
Air Products (APD) to Post Q2 Earnings: What's in the Offing? - Yahoo Finance

Recommendation and review posted by Bethany Smith

Goldman Sachs Asset Management does not expect any interruption to its suite of five thematic equity ETFs launched in partnership with Motif Capital Management after the fintech firm announced it would be shutting it doors.

The five Goldman Sachs thematic equity ETFs target trends that are making transformational changes to the global economy.

Founded in 2010, Motif is an online broker offering thematic portfolios (called motifs) created by professional investors. The platform allows users to buy shares in a motif at a low entry point of just $300.

The firm repurposed some of these portfolios to form the basis of indices, independently calculated by Solactive, which were licensed to Goldman Sachs to underlie a series of ETFs brought to market in March 2019.

The ETFs cover themes tracking transformational changes to the global economy: data-driven world, finance reimagined, human evolution, manufacturing revolution, and new-age consumer.

The funds are listed on NYSE Arca, come with expense ratios of 0.50%, and collectively house around $90 million.

While Motifs business model received support from Silicon Valley investors, picking up over $100m in private equity capital over the years, it appears as though the firm has been unable to reach a position of ongoing economic viability.

And with markets down and client redemptions up as a result of COVID-19, assets under management have likely fallen below a level deemed sustainably feasible.

Motif announced to clients that their assets would be shifted to rival Folio Investing.

According to a statement from Goldman, Motif informed it that it would cease to serve as index provider for the Goldman Sachs ETFs on or about May 15th.

While Motifs pending departure cast some doubt on the future of the ETFs, Goldman has moved quickly to allay investors immediate fears by noting it is in discussions to assume the role of index provider, subject to approval by the ETFs board of trustees.

It says, We do not expect any interruption to the management of the ETFs at the present time, and the ETFs continue to trade on NYSE Arca.

The funds

The Goldman Sachs Motif Data-Driven World ETF (GDAT US) tracks companies poised to benefit from the increasing digitization of data. Stocks are analyzed along five sub-themes including internet of things, data infrastructure, big data, cybersecurity, and artificial intelligence.

The Goldman Sachs Motif Finance Reimagined ETF (GFIN US) tracks companies poised to benefit from developments in the delivery of financial services. Relevant sub-themes include the digitization of finance, the migration to low-cost passive investments, and blockchain technology.

The Goldman Sachs Motif Human Evolution ETF (GDNA US) tracks health care companies that are most likely to benefit from the development of new medical treatments along the sub-themes of precision medicine, genomics, life extension, robotic surgery, and consumer health care.

The Goldman Sachs Motif Manufacturing Revolution ETF (GMAN US) tracks companies incorporating new technologies to optimize the manufacturing process as well as firms involved in the manufacture of new products across the robotics, 3D printing, autonomous vehicles, drones, and clean energy sub-themes.

The Goldman Sachs Motif New Age Consumer ETF (GBUY US) tracks companies most likely to benefit from recent structural changes in the consumer market across demographics, technology, and preferences. Relevant sub-themes include e-commerce, social media, online gaming, online music and video, experiences on goods, and the evolution of education, health, and wellness.

See original here:
GSAM set to assume index responsilities following closure of index partner Motif - ETF Strategy

Recommendation and review posted by Bethany Smith

Since the end of March, Prime Minister Benjamin Netanyahu has been trumpeting a study by the little-known Deep Knowledge Group that claims Israel is the safest country in the world in the fight against the coronavirus pandemic. Amid repeated efforts by journalists, scientists, politicians and concerned social media users to question and even debunk the study, Netanyahu has continued to cite it on prime-time television as well as on his official website and social media feed.

Not only does the study fail to reveal the data or methodology it used, but the people behind it also have strikingly unusual career histories. The Times of Israel has dug further into the founders of the Deep Knowledge Group and discovered a San Francisco-based medical expert with an extraordinary resum who reportedly has run a firm offering private intelligence services to foreign governments; a failed Russian banker who advises the Moldovan president on the economy; and a bizarre Russian movement to prolong the human lifespan.

On March 31, Netanyahu posted a self-congratulatory statistic on his Facebook page, Twitter account and the official website of the Prime Ministers Office. It featured a bar chart entitled Coronavirus Health Safety Countries Ranking, and showed Israel leading the world in countries where an individual could feel most safe during the coronavirus pandemic.

Get The Start-Up Israel's Daily Start-Up by email and never miss our top storiesFree Sign Up

Critics quickly panned [Hebrew link] the study, correctly pointing out that while Israel is by no means the worst affected country in the world, there are many countries with a lower death rate per capita, a higher testing rate and better preparedness than Israel.

A chart prepared by the Deep Knowledge Group and posted on Netanyahus Facebook page on March 31, 2020 showing Israel as the worlds safest country during the coronavirus pandemic (Facebook)

The study itself did not explain its methodology or what data it relied on. It had come from the website of a firm called Deep Knowledge Group that few people had ever heard of.

Netanyahu then cited the safest country ranking during at least two of his frequent appearances on national television when discussing the fight against COVID-19.

The Times of Israel published an article on April 8 revealing that Deep Knowledge Group was a Hong Kong investment capital firm owned by a Moscow- and London-based businessman named Dmitry Kaminskiy with business interests in the fintech, blockchain and longevity industries. In mid-2015, Kaminskiy bought the Russian Interactive Bank and announced in interviews in the Russian media that he would invest $1 billion in the bank to make it the best in the world using artificial intelligence technology. A year later, the bank was bankrupt and its license had been revoked.

Days later, Prof Yitzhak Ben-Israel, head of the Security Studies program at Tel Aviv University, derided (Hebrew link) the sites findings as the mother of fake news, stressing that the rankings were not formal, official or credible.

Despite the many questions raised about Deep Knowledge Groups study, Netanyahu cited it yet again, unwittingly or otherwise, when tweeting on April 15 that Forbes Magazine had now also proclaimed Israel to be the safest place in the world vis-a-vis the coronavirus.

In fact, the Forbes.com article Netanyahu tweeted about, which was published April 13, was written by an executive at the very same Deep Knowledge Group that had authored the March 30 study: Margaretta Colangelo, a San Francisco-based co-founder of Deep Knowledge Group with an impressive resum that included membership in Women Techmakers at Google. Forbes subsequently made clear that it had not conducted any study of its own ranking countries safety in the battle against COVID-19.

Margaretta Colangelo, co-founder of Deep Knowledge Ventures (LinkedIn)

The article was labeled a Forbes Contributor submission. Forbes clarified [Hebrew link] on April 16 that this meant that the [coronavirus] study was published by an external entity and is not a ranking produced by Forbes.

A social media storm ensued, with Israeli supporters of Netanyahu claiming that the findings published in Forbes nevertheless come from a reputable and reliable source and that Forbes vetted its contributors, while detractors alleged that Deep Knowledge Group was a little-known entity that has managed to beef up its online presence through robust PR practices and that its findings lacked credibility and were repeatedly being hyped by Netanyahu to serve his own interests.

While some social media critics questioned Colangelos and DKGs credibility, others rallied to her and her companys defense.

I work at Google, and the name Margaretta Colangelo does not come up in connection with our company, wrote a Facebook poster on April 16.

Guy Levy, a public relations professional and former spokesman for acting Justice Minister Amir Ohana, shot back, Are you in senior management? Because I assume if you are a programmer or even a team leader you would know nothing about Googles work on public health issues.

Levy also claimed in a viral April 15 post that the reputation and credentials of Deep Knowledge Group and Margaretta Colangelo should lay to rest any doubts about the validity of the study.

He added that Deep Knowledge Group has partnered with scientists at Oxford and Cambridge universities.

He said that Margaretta Colangelo is a world expert in her field. She was manager of medical high-tech companies in Silicon Valley for 30 years and among other roles she sits on the board of directors or advises dozens of companies and leading international bodies in the field.

A text message from Margaretta Colangelo to Israeli PR professional Guy Levy (Facebook)

A day later, Levy posted a text message he had received from Colangelo herself in which she enumerated her credentials, Dmitry Kaminskiy and I have written over 100 articles on AI and DeepTech which have been published in Forbes, in MIT Technology Review Italia, Health Management Journal, Asian Robotics Review, The American Journal of Translational Medicine and Pharmaceutical Executive Magazine, and we publish 3 newsletters with over 25,000 subscribers on DeepTech, AI and FinTech, he quoted Colangelo as saying. Im also on the Advisory Board of the AI Precision Health Institute at the University of Hawaii Cancer Centerand on the Advisory Board of the Longevity AI Consortium at Kings College London.

A perusal of Colangelos LinkedIn profile reveals that a large number of the companies and organizations with which she is associated appear to be either subsidiaries or sister companies of Deep Knowledge Group, or startups or nonprofits that have been beneficiaries of its largesse.

Thus, according to Colangelos LinkedIn profile, she is the co-founder of Deep Knowledge Ventures, Longevity Capital, Longevity Bank, Aging Analytics Agency, and Deep Knowledge Analytics, all of which have overlapping owners and/or employees with Deep Knowledge Group.

Meanwhile, the Longevity AI Consortium at Kings College London, where she is an adviser, is funded by her own companies, Deep Knowledge Ventures and Aging Analytics Agency, among others.

A chart prepared by the Deep Knowledge Group still showing Israel as the worlds safest country during the coronavirus pandemic on April 7, 2020 (Screenshot)

The Biogerentology Research Foundation, a British nonprofit founded by Colangelos partner Kaminskiy, has sponsored joint activities with student clubs at Oxford and Cambridge universities, including the Oxford University Scientific Society, the Oxford Longevity Society and the Cambridge Longevity Society.

Colangelo did in fact publish an article, translated from her LinkedIn page, in MIT Technology Review Italia. Some of the other publications where she said she has been published, like Asian Robotics Review and The American Journal of Translational Medicine, appear to be obscure journals with a very limited web presence.

Prior to Deep Knowledge Group, Colangelos LinkedIn profile shows that since 2007 she has been president of U1 Technologies, a company that provides the communications infrastructure for stock trading platforms used by the worlds top multinational investment banks.

An internet search shows that in February 2017 U1 Technologies bid on a contract to build a prototype of US President Donald Trumps proposed border wall with Mexico.

Although it is not mentioned on her LinkedIn profile, Colangelo was described online as recently as 2015 as the CEO of The Delian Group. The Delian Group is a private intelligence company owned by a former CIA intelligence officer named William Ross Newland III, whose services include intelligence operations, intelligence collection, cutting edge security technology, cyber security, cyber operations, social media monitoring, threat detection, political and economic reporting and law enforcement training for clients that include multinational companies, intelligence services, police, military, financial institutions, emergency services, and the mining and energy sectors.

According to Intelligence Online, The Delian Groups owner was also a partner in the private intelligence firm TD International, which reportedly caters to many clients from the former Soviet Union.

The Times of Israel sent questions to Colangelo, asking her about the methodology behind the DKG ranking that placed Israel as the worlds safest country at the end of March and continues to do so even as Israel was statistically about 27th in the world in deaths per capita from the virus as of this weekend and how she thinks the ranking came to Netanyahus attention. We also asked about the background and activities of Deep Knowledge Group and where its money comes from. She had not responded as of publication of this article.

Deep Knowledge Groups other co-founder, Dmitry Kaminskiy, first appeared in the media in 2014. English-language publications from the time do not reveal much about him, but an August 2014 article in Russias Ekspert business weekly described Kaminskiy as an IT specialist involved in banking analytics who recently became interested in futurology and life extension science and had decided to invest in the cancer research of two promising Russian scientists, Anton Buzdin and Alex Zhavoronkov.

Dmitry is also one of those active young people who are interested in many things. And at first he was fascinated by futurologists and fans of artificial intelligence.But, as it turned out a little later, he was even more attracted to the life sciences. He began to develop his horizons in this direction.

Dmitry Kaminskiy (Facebook)

Buzdin and Zhavoronkov were also supported by the state-funded Skolkovo Foundation, making Kaminskiy a co-investor with the Russian government in their cancer research venture. In 2014, the FBIs Boston office warned that the Skolkovo Foundation, a Russian-government-backed innovation fund, was investing in US-based technology firms in order to steal their intellectual property.

The FBI recently released a notification to technology companies and research facilities, which include colleges and universities in the Boston area, warning them of the possible perils of entering into joint partnerships with foreign venture capital firms from Russia, special agent Lucia Ziobro wrote.

According to the Ekspert article, Kaminskiy founded Deep Knowledge Ventures, a venture capital firm, in Hong Kong in 2014, saying he planned to raise money from wealthy Chinese and Russian investors. He said he planned to invest $100 million in life-extension technologies around the world by the end of 2015.

I thought [Hong Kong] was a very favorable place. There is a huge concentration of scientists and extremely wealthy people who are inclined not only to traditional, but also to progressive investments.It has strong legislation and powerful financial institutions, Kaminskiy told Ekspert.

Kaminskiy also founded two nonprofits in Moscow: the Center for Biogerontology and Regenerative Medicine, which develops new methods of treating cancer and anti-aging, as well as the Fund for Supporting Advanced Biotechnologies.

In March of 2019, several companies owned by Kaminskiy published a 577-page report entitled Longevity in Israel, mapping Israels biotech industry, including names and detailed descriptions of hundreds of companies and entrepreneurs.

The study quotes Netanyahu on page 50 regarding a plan to digitize the health records of Israels nearly nine million citizens and open the data up to researchers and entrepreneurs, including people from abroad.

The government is planning to invest in local entrepreneurs and attract foreign investors so that they could come and invest in the country through the data that has been examined and collected by the Israel doctors in their clinics, the report stated.

As the Times of Israel has reported, in March 2018 the Israeli government approved a National Digital Health Plan that would create a digital database of the medical files of some 9 million residents and make them available to researchers and enterprises. Despite assurances that the government would protect Israelis data, privacy advocates warned that the data could be abused. The program is currently in a pilot stage, with the government subsidizing startups that use health data in an innovative way.

Its estimated that almost 98% of the population has been examined and documented on a special digital platform for years now, said the longevity study, adding that Prime Minister Benjamin Netanyahu said in a statement that the Israeli database is a huge asset and we want to give it to researchers, developers and companies. The interest of global companies is tremendous. Ive already met many.

Moldovas President Igor Dodon delivers a brief statement, next to Parliament Speaker Zinaida Greceanii, after a meeting of the countrys Supreme Security Council in Chisinau, Moldova, June 11, 2019. (AP Photo/Roveliu Buga)

According to the Moldovan newspaper Ziarul de Garda, in February 2018, Dmitrii Kaminskiy was chosen to be one of several economic advisers to Moldovan president Igor Dodon.

A source familiar with the Russian economy and Russian business told The Times of Israel that while Kaminskiy has been described as an oligarch in various Russian and English-language publications, he is not a well-known figure in Russia.

According to Harvard University anthropology professor Anya Bernstein, in Russia the effort to lengthen human life through technology is not just an investment opportunity; its a utopian, quasi-religious movement. Bernstein is the author of a 2019 book entitled The Future of Immortality: Remaking Life and Death in Contemporary Russia.

Well before Silicon Valleys recent obsession with immortality, she wrote, from the mid-nineteenth century onward, in Russia, the Soviet Union, and the Russian Federation that succeeded them, the theme of technologically enabled human immortality has been consistent across diverse intellectual circles.

Kaminskiy and other longevity enthusiasts have been active organizing politically, advocating for government investment in and promotion of biotech, artificial intelligence, fintech and blockchain initiatives that will supposedly promote longer lifespans.

Thus in the UK, Kaminskiy helps sponsor the All Party Parliamentary Group for Longevity, while in Israel, Kaminskiys close associate and co-author of his 577-page report on the Israeli Longevity Industry, Ilia Stambler, claims he has been influential in drafting the Knessets masterplan on aging. Kaminskiy and Stambler were both advisers for an initial coin offering of a longevity token for an app designed to promote health and fitness, anti-aging, and personalized health diagnostics.

Stambler, a Moldova-born Israeli who is the director of Research and Development at Shmuel Harofe Geriatric Medical Center in Beer Yaakov, Israel, is the head of the Israel Longevity Alliance and Vetek, the Movement for Longevity and Quality of Life in Israel, which are part of a Russian umbrella organization called the International Longevity Alliance that has chapters in 60 countries, according to the organizations website.

Ilia Stambler (left) and Dmitry Kaminskiy (Facebook)

A third of the funding of the Israel Longevity Alliance/Vetek comes from a Gibraltar-based company known as Media Tower Limited. According to Gibraltars corporate registry, Media Tower Ltd. is 99.9 % owned by Finsbury Nominees Limited and 0.1% owned by Finsbury Holdings Limited. The identity of Media Tower Ltds ultimate beneficial owner is a mystery.

An internet search reveals that Media Tower Limited is an IT Support, Web Development and SEO company based in London that appears to have nothing to do with Israel. It is run by a Latvian man named Helmuts Meskonis who also owns, in partnership with a Russian man named Pavel Sizov, a company known as VLSA that provides clients with a prestigious London address even when they are located elsewhere.

Any UK-registered business and almost all international businesses can get a premium W1 central London business correspondence address from VLSA, the site says. We see ourselves as Swiss-like private and secure business service provider.

Netanyahu is not the only Israeli politician who has been promoting the Deep Knowledge Group study. On April 15, Health Minister Yaakov Litzman issued a statement to the press saying Forbes Magazine has ranked Israel as the safest country from the coronavirus, and in eighth place in terms of the effectiveness of our response. This could not have happened without the dedication of doctors, nurses and everyone doing the holy work of the health system.

Israels leading television news show, N12, also reported the Forbes ranking on its homepage on April 15, before removing the article after being ridiculed on social media and after learning that the Forbes article had not been produced by the magazine itself but was a contributed piece by a co-founder of Deep Knowledge Group.

On April 16, Moshe Yaalon MK, the former Likud defense minister who is now a prominent adversary of Netanyahus, dismissed the ranking and the prime ministers repeated references to it: Israel is the safest in the world? he scoffed in a Channel 12 interview. Its a lie and a fraud.

The criticism may have affected the prime minister as well.

On Saturday night, April 18, when Netanyahu most recently addressed Israelis on national television, he did not cite the Deep Knowledge Group study. Instead, he said, more vaguely, among the developed countries, the OECD member states, Israel is ranked very high in dealing with the coronavirus. The per capita mortality rate in Israel is among the lowest in the OECD. The mortality rate among the sick in Israel is among the lowest in the OECD.

See the rest here:
Behind PM-cited study showing Israel is safest place, a rabbit hole of weirdness - The Times of Israel

Recommendation and review posted by Bethany Smith

The success of approved stem cell therapies has caused a surge in interest of biopharma developers in this field; many innovator companies are currently progressing proprietary leads across different phases of clinical development, with cautious optimism

LONDON, March 4, 2020 /PRNewswire/ -- Roots Analysishas announced the addition of "Global Stem Cells Market: Focus on Clinical Therapies, 20202030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))" report to its list of offerings.

There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years.

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link

Key Market Insights

Over 280 stem cell therapies are under development, most of which are allogeneic products

More than 50% of the pipeline candidates are in the mid to late phase trials (phase II and above), and allogenic therapies (majority of which are derived from the bone marrow) make up 65% of the pipeline.

70% of pipeline candidates are based on mesenchymal stem cells

It is worth highlighting that the abovementioned therapies are designed to treat musculoskeletal (22%), neurological (21%) and cardiovascular (15%) disorders. On the other hand, hematopoietic stem cell-based products are mostly being evaluated for the treatment of oncological disorders, primarily hematological malignancies.

Close to 85% stem cell therapy developers are based in North America and Asia-Pacific regions

Within these regions, the US, China, South Korea and Japan, have emerged as key R&D hubs for stem cell therapies. It is worth noting that majority of the initiatives in this domain are driven by small / mid-sized companies

Over 1,500 grants were awarded for stem cell research, since 2015

More than 45% of the total amount was awarded under the R01 mechanism (which supports research projects). The NCI, NHLBI, NICHD, NIDDK, NIGMS and OD emerged as key organizations that have offered financial support for time periods exceeding 25 years as well.

Outsourcing has become indispensable to R&D and manufacturing activity in this domain

Presently, more than 80 industry / non-industry players, based in different regions across the globe, claim to provide contract development and manufacturing services to cater to the unmet needs of therapy developers. Examples include (in alphabetical order) Bio Elpida, Cell and Gene Therapy Catapult, Cell Tech Pharmed, GenCure, KBI Biopharma, Lonza, MEDINET, Nikon CeLL innovation, Roslin Cell Therapies, WuXi Advanced Therapies and YposKesi.

North America and Asia-Pacific markets are anticipated to capture over 80% share by 2030

The stem cell therapies market is anticipated to witness an annualized growth rate of over 30% during the next decade. Interestingly, the market in China / broader Asia-Pacific region is anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom stem cell therapies are currently considered to be a promising alternatives for the treatment of a myriad of disease indications, with the potential to overcome challenges associated with conventional treatment options. The report includes detailed transcripts of discussions held with the following experts:

The research covers brief profiles of several companies (including those listed below); each profile features an overview of the company, financial information (if available), stem cell therapy portfolio and an informed future outlook.

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html email sales@rootsanalysis.com

You may also be interested in the following titles:

Contact:Gaurav Chaudhary+1(415)800-3415+44(122)391-1091Gaurav.Chaudhary@rootsanalysis.com

Logo: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg

SOURCE Roots Analysis

See the article here:
With Over 280 Therapies Under Evaluation, the Stem Cell Therapy Market is Estimated to be Worth USD 8.5 Billion by 2030, Claims Roots Analysis - PR...

Recommendation and review posted by Bethany Smith

Detailed market survey on the Global Autologous Stem Cell Based Therapies Market Research Report 2020-2026. It analyses the vital factors of the Autologous Stem Cell Based Therapies market supported present business Strategy, Autologous Stem Cell Based Therapies market demands, business methods utilised by Autologous Stem Cell Based Therapies market players and therefore the future prospects from numerous angles well. Business associatealysis could be a market assessment tool utilized by business and analysts to grasp the quality of an business. Autologous Stem Cell Based Therapies Market report It helps them get a sense of what is happening in an industry, i.e., demand-supply statistics, Autologous Stem Cell Based Therapies Market degree of competition within the industry, Autologous Stem Cell Based Therapies Market competition of the business with different rising industries, future prospects of the business.

NOTE: Our reports include the analysis of the impact of COVID-19 on this industry. Our new sample is updated which correspond in new report showing impact of Covid-19 on Industry trends. Also we are offering 20% discount

Obtain sample copy of Autologous Stem Cell Based Therapies market report: https://calibreresearch.com/report/global-autologous-stem-cell-based-therapies-market-4316#request-sample

The Global Autologous Stem Cell Based Therapies Market report is a fully analyzed and intelligent study of the international industry that focuses on a wide range of significant elements such as market size in terms of value and volume, regional growth analysis, competition and segmentation. It is considered as extraordinary findings that accountable to offer insightful details into some essential attributes related to the global Autologous Stem Cell Based Therapies Market 2020. The detailed investigation of this report has been carried out by the list of skillful researchers and investigators with a deep analysis of current industry trends, availability of distinct opportunities, drivers, openings and limitation that influence the Autologous Stem Cell Based Therapies Market on the global scale.

The Global Autologous Stem Cell Based Therapies market worth about xx billion USD in 2020 and it is expected to reach xx billion USD in 2026 with an average growth rate of x%. United States is the largest production of Autologous Stem Cell Based Therapies Market and consumption region in the world, Europe also play important roles in global Autologous Stem Cell Based Therapies market while China is fastest growing region.

Checkout Inquiry For Buying or Customization of Autologous Stem Cell Based Therapies Market Report: https://calibreresearch.com/report/global-autologous-stem-cell-based-therapies-market-4316#inquiry-for-buying

Geographically, Autologous Stem Cell Based Therapies market report is segmented into several key Regions, with production, consumption, revenue. The major regions involved in Autologous Stem Cell Based Therapies Market are (United States, EU, China, and Japan).

Leading companies reviewed in the Autologous Stem Cell Based Therapies report are:

RegeneusMesoblastPluristem Therapeutics IncU.S. STEM CELL, INC.Brainstorm Cell TherapeuticsTigenixMed cell Europe

Autologous Stem Cell Based Therapies Market Product Type Segmentation As Provided Below:The Autologous Stem Cell Based Therapies Market report is segmented into following categories:

The product segment of the report offers product market information such as demand, supply and market value of the product.

The application of product in terms of USD value is represented in numerical and graphical format for all the major regional markets.The Autologous Stem Cell Based Therapies market report is segmented into Type by following categories;Embryonic Stem CellResident Cardiac Stem CellsUmbilical Cord Blood Stem Cells

The Autologous Stem Cell Based Therapies market report is segmented into Application by following categories;Neurodegenerative DisordersAutoimmune DiseasesCardiovascular Diseases

Reportedly, the massive growth graph in the research and development sectors will be liable to generate plenty of excellent opportunities in the upcoming years. The Autologous Stem Cell Based Therapies market is a valuable resource of insightful information for specific business strategists. Apart from this, it also offers an in-depth summary of the Autologous Stem Cell Based Therapies Market along with growth assessment, revenue share, demand & supply data, historical as well as futuristic amount etc. A group of research analysts offers a detailed description of the value chain and its distributors info. Moreover, the Autologous Stem Cell Based Therapies market study report delivers comprehensive information regarding the global industry that enhances the scope, understanding and application of the same.

Checkout FREE Report Sample of Autologous Stem Cell Based Therapies Market Report for Better Understanding: https://calibreresearch.com/report/global-autologous-stem-cell-based-therapies-market-4316#request-sample

Industry analysis, for an entrepreneur or a company, is a method that helps it to understand its position relative to other participants in the Autologous Stem Cell Based Therapies Market. It helps them to identify both the opportunities and threats coming their way and gives them a strong idea of the present and future scenario of the Autologous Stem Cell Based Therapies industry. The key to extant during this changing business setting is to know the variations between yourself and your competitors within the Autologous Stem Cell Based Therapies Market. The deep research study of Autologous Stem Cell Based Therapies market based on development opportunities, growth limiting factors and feasibility of investment will forecast the Autologous Stem Cell Based Therapies market growth.

Finally, The global research document on the Autologous Stem Cell Based Therapies Market discovers a large set of information regarding the competitive business environment and other substantial components. The prime aim of these major competitors is to focus on improved technologies and newer innovations.

More here:
Study on Autologous Stem Cell Based Therapies Market (impact of COVID-19) 2020-2026 Brainstorm Cell Therapeutics, Tigenix, Med cell Europe - Bandera...

Recommendation and review posted by Bethany Smith

]]> To build the digital twin, engineers at Akselos needed to collect all available data on the gigantic asset which could then be used to create a 3D rendered structural digital model. Credit: Joe King

Originally designed in the 1960s, with engineering work completed in the 1970s, the Turlough Hill hydroelectric power station in Ireland is reaching the end of its design life.

However, the plant, which is the only pumped storage station in Ireland, is still a key asset for its owner and operator ESB and helps stabilise the local grid at times of peak demand.

Keen to explore ways to potentially extend the power stations life, in October last year ESB brought in software provider Akselos to create a digital view of the asset.

Using its predictive and digital design technology, Akselos has created a detailed digital twin of the Turlough plant and is working on building a Digital Guardian of the asset which Akselos says can extend its useful life by up to twenty years.

Located approximately 60km south of Dublin in the Wicklow Mountains, the Turlough Hill hydroelectric power station generates 292MW during peak demand periods by releasing water from its upper reservoir and allowing it to flow through its four turbines into a lower reservoir.

During periods of lower demand the water is pumped back to the upper reservoir ready to be used again.

The energy storage that Turlough provides is increasingly important in the changing energy ecosystem, which is moving towards more flexibility to incorporate renewables. But due to its age and size, ESB does not know how much structural life the hydro plant has left and whether its operations can be made more responsive in the future.

As part of the Free Electrons Accelerator Programme an initiative to connect startups with energy utilities to support and foster innovation ESB was introduced to Akselos to help find some answers.

The challenge for ESB is how to continue to operate and on what basis? Thats what the digital twin can help answer, says AndrewYoung,Akselos VP of projects and delivery.

To build the digital twin, engineers at Akselos needed to collect all available data on the gigantic asset which could then be used to create a 3D rendered structural digital model.

This task was made harder, however, by the lack of available digital information. Akselos engineers had to work with paper records only, which put the project behind by two months. In total, it took five months to complete.

To build the model, it was key to establish the geometries, interactions and stresses in the plant system to create an intuitive heat map. The map can show when and what tensions are running through the power station and direct maintenance inspections to specific areas of concern, rather than just doing a random walk through.

The digital twin is essentially a tool with which ESB can simulate many parameters around the day to day operation of the plant and visually pan through the entire structure and see how it reacts.

Our technology allows maintenance engineers to really pinpoint, using rules of science and engineering, where the issues will likely occur and we can also establish what the operational life is in terms of fatigue assessment. It also supports predictive maintenance, says Young.

An inspection can cost around 3-5m, through a combination of lost production and penalties for down time, so the technology can potentially save companies money.

Young estimates the CAPEX invested for Akselos digital twin technology by a utility can be recouped within a three year period, just on the basis of improved inspection. Furthermore, he says it can provide a 20-50% life extension.

Predictive maintenance is not new. Bigger companies such as ABB and GE also offer this technology; so what makes Akselos offering different?

According to Young, existing predictive maintenance modelling and applications typically use asset management tools to achieve around 30% predictive. However, Akselos add a scientifically based structural integrity component.

We can simulate future events because of the nature of our physics-based twin, whereas what other companies are doing is assessing the probability of a known and identified defect reoccurring, explains Young.

Essentially, Akselos software assesses and identifies the risk of any type of failure based on the structural assessment; a fault doesnt have to already be pre-identified.

A GE report notes that structural integrity provides a 90% predictive capability, so we believe it is actually complementary to what companies like GE are doing, but gives a higher level of understanding of the asset, he adds.

In fact, Young says the company is currently in the assessment phase of several projects with OEMs, which he cant name, on integrating Akselos technology within their offering.

These companies are starting to offer digital twins with every piece of kit they sell, and in the future, if they deliver a twelve-megawatt wind farm, it will have Akselos software inside, running as par of their predictive capability offering, says Young.

Now the digital twin of the Turlough Hill hydroelectric power station is built, the next stage of the project would be to create a Digital Guardian, says Young. To do this, engineers will connect specially placed sensors to get a real time picture of what is happening in the hydro plant. This is expected to be planned for the next maintenance window.

Through the models, ESB will look to assess different modes of operation that might better work alongside renewables, such as storing electricity at different times of the day.

An additional model of operation could be pumping in the daytime to store power when its needed, in addition to at night, as renewable energy sources are changing the dynamics of energy supply and pricing, explains Young.

This means rather than having one cycle a day, the plant might have two or more. However, Turlough wasnt designed to operate in this way, therefore ESB needs to understand what the impact might be on the structure. These factors, added to aging asset management risks, could increase inspection frequencies and costs or even require a significant CAPEX project.

Using Akselos technology, Young says there is no reason why the life of the asset could not be extended another 20 years.

I dont think ESB came on board just to do a pilot, I think the company is really interested in this technology and how they can apply it to different assets, says Young.

Adopting the innovation is largely about adapting to the changing energy ecosystem sooner rather than later, and becoming more efficient and more cost effective in the process.

Legacy assets still have to be managed for some years despite the energy transition, and theyre looking for cost effective ways to do this, says Young.

The utility industry is one of the first to encounter huge disruption and ESB is adapting to it extremely well by applying innovation to find new business models, this is what were hoping to do.

Read more:
Inside the world's first digital twin of a hydroelectric power station - Power Technology

Recommendation and review posted by Bethany Smith

The decline in economic activity precipitated by the spread of COVID-19 and ensuing lockdown in South Africa is also affecting the countrys electricity supply dynamics. The power outages that were disrupting the economy just a month earlier are suddenly contained. Electricity demand in the lockdown period has decreased by about 7,500MW, corresponding to almost a quarter of its normal peak capacity.

Given that Eskom, the national power utility, is using the lockdown period for some of its regular plant maintenance routines, more reliable supply can be expected in the latter part of the year. Electricity demand is likely to remain suppressed after the lockdown but this relief wont extend for more than a few months.

The utility has had some success in keeping many of its vulnerable generating plants operational, and is adopting a more rigorous maintenance regime. But electricity production capacity remains critically low.

When the country finally emerges from COVID-19, it will face a severely damaged economy requiring a massive rebuild. The electricity supply shortage will once again rear its head.

Some help could be provided by renewable energy projects scheduled to come on stream this year.

These include 12 solar farms and 12 wind farms. The first two developments were completed in February.

Construction for these plants was initiated in 2018 following the leadership change in the ruling African National Congress, after a three-year delay.

While the 2,177MW of power provided by these 24 new solar and wind projects appears to be substantial, one must remember that this output corresponds to optimal generating conditions (fresh winds and an overhead sun). In reality, in view of variable weather conditions and the day/night cycle, these plants produce roughly the same amount of electricity as just one of the six units of a large coal plant such as Duvha running non-stop. This is less than the 1,000MW that corresponds to stage one of loadshedding (the phased limitation of supply).

Its therefore essential to expedite the process leading to the development of more generation capacity beyond those currently under construction.

One important hurdle that has been cleared is the adoption of the updated Integrated Resource Plan for electricity last year. This blueprint, which is supposed to be revised every two years, had previously not been updated since 2011.

Several drafts had been produced in the interim, but none were adopted by government. This was presumably because these interim drafts recommended an energy mix that excluded any new nuclear build, a programme that the administration of former president Jacob Zuma was strongly in favour of.

The now official Integrated Resource Plan envisages the steady growth of the renewable energy fraction at the expense of old coal plants, which would gradually be decommissioned.

In particular, the plan would add 1,600MW of wind power each year from 2022 to 2030, as well 6,000MW of new solar energy for that period (starting with 1,000MW in 2022).

Also envisaged for this nine-year time span are two new 750MW coal plants, with the first up and running in 2023, a total of 3,000MW from gas plants (the first of which is supposed to be operational in 2024), and 2,500MW from the Grand Inga dam on the Congo river.

Some relief of the power shortages will come from the presently partly operational Medupi and Kusile megaprojects, whose much-postponed commissioning is expected in the coming few years, and the planned life extension of the Koeberg nuclear plant (which will however not provide extra capacity). But these measures wont suffice to mitigate the closures of the old coal plants.

Some of the new builds are already in doubt. The Grand Inga project, tentatively scheduled for completion in 2030, is facing serious challenges. The future of the newly planned coal plants is also in question. As a primary driver of global warming, coal power is being increasingly maligned, and a large number of potential funding agencies now have policies not to support any coal project. That means that, at least in the medium term, newly initiated projects will be restricted to renewable energy and gas.

Solar and wind projects have a short construction time. The challenge is the regulatory and administrative hurdles that must be cleared before a project can go ahead. These relate to bid submission, review and selection, financial closure and signing of contracts with Eskom. Before the stalling of the Renewable Energy Independent Power Producer Procurement Programme in 2015, the time between the bidding call and plant commissioning was typically three years. That would make the projected 2022 completion date for the next batch or projects practically unachievable.

There are also concerns that the government and the electricity regulator arent demonstrating the required urgency to kickstart a new round of projects. Renewables are perceived as a direct threat to the coal industry, and trade unions allied to the governing party organising in the coal sector are particularly anxious about the inevitable energy transition. Theres also a feeling in some quarters that the mining and energy minister, Gwede Mantashe, a former mining sector unionist, is siding with the coal sector.

But there is a glimmer of hope. Mantashe has just issued two determinations for the procurement of considerable additional power generating capacity.

The first determination is for 2,000MW of emergency power of any technology. Its 2022 completion deadline cannot realistically be met by new builds, so it remains to be seen if the targeted capacity can be achieved by innovative short-term solutions, such as increasing the maximum capacity of existing plants.

The second determination is guided by the Integrated Resource Plan 2019: 4,800MW wind and 2,000MW solar required between 2022 and 2024, 3,000MW gas and 1,500MW coal up to 2027 and 513MW in storage capacity. With several procedural steps still required that show no sign of being expedited, its unlikely that proposals for new power plants will be requested before much later this year.

These plants will then most likely only become operational in late 2023, meaning that the power system will remain vulnerable until then.

Read this article:
Power shortages will remain a big challenge in a post-COVID-19 South Africa - The Conversation Africa

Recommendation and review posted by Bethany Smith

The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Magnolia Bark Extract market. It includes Porters Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Magnolia Bark Extract Market. We have provided deep analysis of the vendor landscape to give you a complete picture of current and future competitive scenarios of the global Magnolia Bark Extract market. Our analysts use the latest primary and secondary research techniques and tools to prepare comprehensive and accurate market research reports. They have also provided accurate data on Magnolia Bark Extract production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Magnolia Bark Extract market include : , Swanson, Samsara herbs, Genesis Today, Planetary Herbals, Solaray, Active Herb, LiftMode, Life Extension, thepurehealth, Hawaii Pharm LLC, Piping Rock Health Products, Now Foods Source Naturals

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1557590/global-magnolia-bark-extract-market

Each segment of the global Magnolia Bark Extract market is extensively evaluated in the research study. The segmental analysis offered in the report pinpoints key opportunities available in the global Magnolia Bark Extract market through leading segments. The regional study of the global Magnolia Bark Extract market included in the report helps readers to gain a sound understanding of the development of different geographical markets in recent years and also going forth. We have provided a detailed study on the critical dynamics of the global Magnolia Bark Extract market, which include the market influence and market effect factors, drivers, challenges, restraints, trends, and prospects. The research study also includes other types of analysis such as qualitative and quantitative.

Global Magnolia Bark Extract Market: Competitive Rivalry

The chapter on company profiles studies the various companies operating in the global Magnolia Bark Extract market. It evaluates the financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years. Analysts have also provided a detailed list of the strategic initiatives taken by the Magnolia Bark Extract market participants in the past few years to remain ahead of the competition.

Key players cited in the report

, Swanson, Samsara herbs, Genesis Today, Planetary Herbals, Solaray, Active Herb, LiftMode, Life Extension, thepurehealth, Hawaii Pharm LLC, Piping Rock Health Products, Now Foods Source Naturals

Global Magnolia Bark Extract Market: Type Segments

, Solid Form, Powder Form

Global Magnolia Bark Extract Market: Application Segments

, Pharmaceutical, Food and Beverages, Others

Global Magnolia Bark Extract Market: Regional Segments

The chapter on regional segmentation details the regional aspects of the global Magnolia Bark Extract market. This chapter explains the regulatory framework that is likely to impact the overall market. It highlights the political scenario in the market and the anticipates its influence on the global Magnolia Bark Extract market.

The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Key questions answered in the report:

Enquire for customization in the Report @https://www.qyresearch.com/customize-request/form/1557590/global-magnolia-bark-extract-market

Table of Contents

Table of Contents 1 Magnolia Bark Extract Market Overview1.1 Magnolia Bark Extract Product Overview1.2 Magnolia Bark Extract Market Segment by Type1.2.1 Solid Form1.2.2 Powder Form1.3 Global Magnolia Bark Extract Market Size by Type (2015-2026)1.3.1 Global Magnolia Bark Extract Market Size Overview by Type (2015-2026)1.3.2 Global Magnolia Bark Extract Historic Market Size Review by Type (2015-2020)1.3.2.1 Global Magnolia Bark Extract Sales Market Share Breakdown by Type (2015-2026)1.3.2.2 Global Magnolia Bark Extract Revenue Market Share Breakdown by Type (2015-2026)1.3.2.3 Global Magnolia Bark Extract Average Selling Price (ASP) by Type (2015-2026)1.3.3 Global Magnolia Bark Extract Market Size Forecast by Type (2021-2026)1.3.3.1 Global Magnolia Bark Extract Sales Market Share Breakdown by Application (2021-2026)1.3.3.2 Global Magnolia Bark Extract Revenue Market Share Breakdown by Application (2021-2026)1.3.3.3 Global Magnolia Bark Extract Average Selling Price (ASP) by Application (2021-2026)1.4 Key Regions Market Size Segment by Type (2015-2020)1.4.1 North America Magnolia Bark Extract Sales Breakdown by Type (2015-2026)1.4.2 Europe Magnolia Bark Extract Sales Breakdown by Type (2015-2026)1.4.3 Asia-Pacific Magnolia Bark Extract Sales Breakdown by Type (2015-2026)1.4.4 Latin America Magnolia Bark Extract Sales Breakdown by Type (2015-2026)1.4.5 Middle East and Africa Magnolia Bark Extract Sales Breakdown by Type (2015-2026) 2 Global Magnolia Bark Extract Market Competition by Company2.1 Global Top Players by Magnolia Bark Extract Sales (2015-2020)2.2 Global Top Players by Magnolia Bark Extract Revenue (2015-2020)2.3 Global Top Players Magnolia Bark Extract Average Selling Price (ASP) (2015-2020)2.4 Global Top Manufacturers Magnolia Bark Extract Manufacturing Base Distribution, Sales Area, Product Type2.5 Magnolia Bark Extract Market Competitive Situation and Trends2.5.1 Magnolia Bark Extract Market Concentration Rate (2015-2020)2.5.2 Global 5 and 10 Largest Manufacturers by Magnolia Bark Extract Sales and Revenue in 20192.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Magnolia Bark Extract as of 2019)2.7 Date of Key Manufacturers Enter into Magnolia Bark Extract Market2.8 Key Manufacturers Magnolia Bark Extract Product Offered2.9 Mergers & Acquisitions, Expansion 3 Global Magnolia Bark Extract Status and Outlook by Region (2015-2026)3.1 Global Magnolia Bark Extract Market Size and CAGR by Region: 2015 VS 2020 VS 20263.2 Global Magnolia Bark Extract Market Size Market Share by Region (2015-2020)3.2.1 Global Magnolia Bark Extract Sales Market Share by Region (2015-2020)3.2.2 Global Magnolia Bark Extract Revenue Market Share by Region (2015-2020)3.2.3 Global Magnolia Bark Extract Sales, Revenue, Price and Gross Margin (2015-2020)3.3 Global Magnolia Bark Extract Market Size Market Share by Region (2021-2026)3.3.1 Global Magnolia Bark Extract Sales Market Share by Region (2021-2026)3.3.2 Global Magnolia Bark Extract Revenue Market Share by Region (2021-2026)3.3.3 Global Magnolia Bark Extract Sales, Revenue, Price and Gross Margin (2021-2026)3.4 North America Magnolia Bark Extract Market Size YoY Growth (2015-2026)3.4.1 North America Magnolia Bark Extract Revenue YoY Growth (2015-2026)3.4.2 North America Magnolia Bark Extract Sales YoY Growth (2015-2026)3.5 Asia-Pacific Magnolia Bark Extract Market Size YoY Growth (2015-2026)3.5.1 Asia-Pacific Magnolia Bark Extract Revenue YoY Growth (2015-2026)3.5.2 Asia-Pacific Magnolia Bark Extract Sales YoY Growth (2015-2026)3.6 Europe Magnolia Bark Extract Market Size YoY Growth (2015-2026)3.6.1 Europe Magnolia Bark Extract Revenue YoY Growth (2015-2026)3.6.2 Europe Magnolia Bark Extract Sales YoY Growth (2015-2026)3.7 Latin America Magnolia Bark Extract Market Size YoY Growth (2015-2026)3.7.1 Latin America Magnolia Bark Extract Revenue YoY Growth (2015-2026)3.7.2 Latin America Magnolia Bark Extract Sales YoY Growth (2015-2026)3.8 Middle East and Africa Magnolia Bark Extract Market Size YoY Growth (2015-2026)3.8.1 Middle East and Africa Magnolia Bark Extract Revenue YoY Growth (2015-2026)3.8.2 Middle East and Africa Magnolia Bark Extract Sales YoY Growth (2015-2026) 4 Global Magnolia Bark Extract by Application4.1 Magnolia Bark Extract Segment by Application4.1.1 Pharmaceutical4.1.2 Food and Beverages4.1.3 Others4.2 Global Magnolia Bark Extract Sales by Application: 2015 VS 2020 VS 20264.3 Global Magnolia Bark Extract Historic Sales by Application (2015-2020)4.4 Global Magnolia Bark Extract Forecasted Sales by Application (2021-2026)4.5 Key Regions Magnolia Bark Extract Market Size by Application4.5.1 North America Magnolia Bark Extract by Application4.5.2 Europe Magnolia Bark Extract by Application4.5.3 Asia-Pacific Magnolia Bark Extract by Application4.5.4 Latin America Magnolia Bark Extract by Application4.5.5 Middle East and Africa Magnolia Bark Extract by Application 5 North America Magnolia Bark Extract Market Size by Country (2015-2026)5.1 North America Market Size Market Share by Country (2015-2020)5.1.1 North America Magnolia Bark Extract Sales Market Share by Country (2015-2020)5.1.2 North America Magnolia Bark Extract Revenue Market Share by Country (2015-2020)5.2 North America Market Size Market Share by Country (2021-2026)5.2.1 North America Magnolia Bark Extract Sales Market Share by Country (2021-2026)5.2.2 North America Magnolia Bark Extract Revenue Market Share by Country (2021-2026)5.3 North America Market Size YoY Growth by Country5.3.1 U.S. Magnolia Bark Extract Market Size YoY Growth (2015-2026)5.3.2 Canada Magnolia Bark Extract Market Size YoY Growth (2015-2026) 6 Europe Magnolia Bark Extract Market Size by Country (2015-2026)6.1 Europe Market Size Market Share by Country (2015-2020)6.1.1 Europe Magnolia Bark Extract Sales Market Share by Country (2015-2020)6.1.2 Europe Magnolia Bark Extract Revenue Market Share by Country (2015-2020)6.2 Europe Market Size Market Share by Country (2021-2026)6.2.1 Europe Magnolia Bark Extract Sales Market Share by Country (2021-2026)6.2.2 Europe Magnolia Bark Extract Revenue Market Share by Country (2021-2026)6.3 Europe Market Size YoY Growth by Country6.3.1 Germany Magnolia Bark Extract Market Size YoY Growth (2015-2026)6.3.2 France Magnolia Bark Extract Market Size YoY Growth (2015-2026)6.3.3 U.K. Magnolia Bark Extract Market Size YoY Growth (2015-2026)6.3.4 Italy Magnolia Bark Extract Market Size YoY Growth (2015-2026)6.3.5 Russia Magnolia Bark Extract Market Size YoY Growth (2015-2026) 7 Asia-Pacific Magnolia Bark Extract Market Size by Country (2015-2026)7.1 Asia-Pacific Market Size Market Share by Country (2015-2020)7.1.1 Asia-Pacific Magnolia Bark Extract Sales Market Share by Country (2015-2020)7.1.2 Asia-Pacific Magnolia Bark Extract Revenue Market Share by Country (2015-2020)7.2 Asia-Pacific Market Size Market Share by Country (2021-2026)7.2.1 Asia-Pacific Magnolia Bark Extract Sales Market Share by Country (2021-2026)7.2.2 Asia-Pacific Magnolia Bark Extract Revenue Market Share by Country (2021-2026)7.3 Asia-Pacific Market Size YoY Growth by Country7.3.1 China Magnolia Bark Extract Market Size YoY Growth (2015-2026)7.3.2 Japan Magnolia Bark Extract Market Size YoY Growth (2015-2026)7.3.3 South Korea Magnolia Bark Extract Market Size YoY Growth (2015-2026)7.3.4 India Magnolia Bark Extract Market Size YoY Growth (2015-2026)7.3.5 Australia Magnolia Bark Extract Market Size YoY Growth (2015-2026)7.3.6 Taiwan Magnolia Bark Extract Market Size YoY Growth (2015-2026)7.3.7 Indonesia Magnolia Bark Extract Market Size YoY Growth (2015-2026)7.3.8 Thailand Magnolia Bark Extract Market Size YoY Growth (2015-2026)7.3.9 Malaysia Magnolia Bark Extract Market Size YoY Growth (2015-2026)7.3.10 Philippines Magnolia Bark Extract Market Size YoY Growth (2015-2026)7.3.11 Vietnam Magnolia Bark Extract Market Size YoY Growth (2015-2026) 8 Latin America Magnolia Bark Extract Market Size by Country (2015-2026)8.1 Latin America Market Size Market Share by Country (2015-2020)8.1.1 Latin America Magnolia Bark Extract Sales Market Share by Country (2015-2020)8.1.2 Latin America Magnolia Bark Extract Revenue Market Share by Country (2015-2020)8.2 Latin America Market Size Market Share by Country (2021-2026)8.2.1 Latin America Magnolia Bark Extract Sales Market Share by Country (2021-2026)8.2.2 Latin America Magnolia Bark Extract Revenue Market Share by Country (2021-2026)8.3 Latin America Market Size YoY Growth by Country8.3.1 Mexico Magnolia Bark Extract Market Size YoY Growth (2015-2026)8.3.2 Brazil Magnolia Bark Extract Market Size YoY Growth (2015-2026)8.3.3 Argentina Magnolia Bark Extract Market Size YoY Growth (2015-2026) 9 Middle East and Africa Magnolia Bark Extract Market Size by Country (2015-2026)9.1 Middle East and Africa Market Size Market Share by Country (2015-2020)9.1.1 Middle East and Africa Magnolia Bark Extract Sales Market Share by Country (2015-2020)9.1.2 Middle East and Africa Magnolia Bark Extract Revenue Market Share by Country (2015-2020)9.2 Middle East and Africa Market Size Market Share by Country (2021-2026)9.2.1 Middle East and Africa Magnolia Bark Extract Sales Market Share by Country (2021-2026)9.2.2 Middle East and Africa Magnolia Bark Extract Revenue Market Share by Country (2021-2026)9.3 Middle East and Africa Market Size YoY Growth by Country9.3.1 Turkey Magnolia Bark Extract Market Size YoY Growth (2015-2026)9.3.2 Saudi Arabia Magnolia Bark Extract Market Size YoY Growth (2015-2026)9.3.3 U.A.E Magnolia Bark Extract Market Size YoY Growth (2015-2026) 10 Company Profiles and Key Figures in Magnolia Bark Extract Business10.1 Swanson10.1.1 Swanson Corporation Information10.1.2 Swanson Description, Business Overview and Total Revenue10.1.3 Swanson Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)10.1.4 Swanson Magnolia Bark Extract Products Offered10.1.5 Swanson Recent Development10.2 Samsara herbs10.2.1 Samsara herbs Corporation Information10.2.2 Samsara herbs Description, Business Overview and Total Revenue10.2.3 Samsara herbs Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)10.2.5 Samsara herbs Recent Development10.3 Genesis Today10.3.1 Genesis Today Corporation Information10.3.2 Genesis Today Description, Business Overview and Total Revenue10.3.3 Genesis Today Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)10.3.4 Genesis Today Magnolia Bark Extract Products Offered10.3.5 Genesis Today Recent Development10.4 Planetary Herbals10.4.1 Planetary Herbals Corporation Information10.4.2 Planetary Herbals Description, Business Overview and Total Revenue10.4.3 Planetary Herbals Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)10.4.4 Planetary Herbals Magnolia Bark Extract Products Offered10.4.5 Planetary Herbals Recent Development10.5 Solaray10.5.1 Solaray Corporation Information10.5.2 Solaray Description, Business Overview and Total Revenue10.5.3 Solaray Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)10.5.4 Solaray Magnolia Bark Extract Products Offered10.5.5 Solaray Recent Development10.6 Active Herb10.6.1 Active Herb Corporation Information10.6.2 Active Herb Description, Business Overview and Total Revenue10.6.3 Active Herb Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)10.6.4 Active Herb Magnolia Bark Extract Products Offered10.6.5 Active Herb Recent Development10.7 LiftMode10.7.1 LiftMode Corporation Information10.7.2 LiftMode Description, Business Overview and Total Revenue10.7.3 LiftMode Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)10.7.4 LiftMode Magnolia Bark Extract Products Offered10.7.5 LiftMode Recent Development10.8 Life Extension10.8.1 Life Extension Corporation Information10.8.2 Life Extension Description, Business Overview and Total Revenue10.8.3 Life Extension Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)10.8.4 Life Extension Magnolia Bark Extract Products Offered10.8.5 Life Extension Recent Development10.9 thepurehealth10.9.1 thepurehealth Corporation Information10.9.2 thepurehealth Description, Business Overview and Total Revenue10.9.3 thepurehealth Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)10.9.4 thepurehealth Magnolia Bark Extract Products Offered10.9.5 thepurehealth Recent Development10.10 Hawaii Pharm LLC10.10.1 Company Basic Information, Manufacturing Base and Competitors10.10.2 Magnolia Bark Extract Product Category, Application and Specification10.10.3 Hawaii Pharm LLC Magnolia Bark Extract Sales, Revenue, Price and Gross Margin (2015-2020)10.10.4 Main Business Overview10.10.5 Hawaii Pharm LLC Recent Development10.11 Piping Rock Health Products10.11.1 Piping Rock Health Products Corporation Information10.11.2 Piping Rock Health Products Description, Business Overview and Total Revenue10.11.3 Piping Rock Health Products Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)10.11.4 Piping Rock Health Products Magnolia Bark Extract Products Offered10.11.5 Piping Rock Health Products Recent Development10.12 Now Foods Source Naturals10.12.1 Now Foods Source Naturals Corporation Information10.12.2 Now Foods Source Naturals Description, Business Overview and Total Revenue10.12.3 Now Foods Source Naturals Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)10.12.4 Now Foods Source Naturals Magnolia Bark Extract Products Offered10.12.5 Now Foods Source Naturals Recent Development 11 Magnolia Bark Extract Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis11.1 Magnolia Bark Extract Key Raw Materials11.1.1 Key Raw Materials11.1.2 Key Raw Materials Price11.1.3 Raw Materials Key Suppliers11.2 Manufacturing Cost Structure11.2.1 Raw Materials11.2.2 Labor Cost11.2.3 Manufacturing Expenses11.3 Magnolia Bark Extract Industrial Chain Analysis11.4 Market Opportunities, Challenges, Risks and Influences Factors Analysis11.4.1 Market Opportunities and Drivers11.4.2 Market Challenges11.4.3 Market Risks11.4.4 Porters Five Forces Analysis 12 Market Strategy Analysis, Distributors12.1 Sales Channel12.2 Distributors12.3 Downstream Customers 13 Research Findings and Conclusion 14 Appendix14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Author Details14.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

Read more:
Magnolia Bark Extract Market Overview With Detailed Analysis, Competitive Landscape, Forecast to 2026|Swanson, Samsara herbs - Jewish Life News

Recommendation and review posted by Bethany Smith

Hydro-Electric Projects face a number of hurdles, both naturaland man-made. The major natural hurdles encountered in hydro-electric power projects are natural calamities (such as earthquake, flood),geological uncertainties, difficult terrain, land slide, poor accessibility, etc.

The examples of man-made hurdles are land acquisition problems,local agitations / resistance including Rehabilitation & Resettlement issues,delay in various statutory clearances viz. Environment and Forest Clearances, Contractual problems, Funds constraints with Developers /Contractors, Inter-State disputes, Court / various Tribunals such as National Green Tribunal (NGT) cases, etc.

The following steps have been taken by the Government to address these hurdles:

Central Electricity Authority (CEA) monitors the progress of under construction power projects through frequent site visits and interaction with the developers and equipment suppliers. CEA holdsreview meetings periodically with the developers and otherstakeholders to identify and resolve issues critical for commissioning of Projects.

Regular reviews are also undertaken in Ministry of Power to identify the constraints areas and facilitate faster resolution of inter-ministerial and other outstanding issues.

A Power Project Monitoring Panel (PPMP), set up by the Ministry of Power, independently monitors the progress of the Projects.

Progress of selected Projects are also reviewed by the Honble Prime Minister through the PRAGATI meetings, as and whenrequired.

In case of Central Public Sector Undertakings (CPSUs), the projectimplementation parameters / milestones are incorporated in the MoU signed every year between respective CPSUs and MoP and the sameare monitored during the Quarterly Performance Review (QPR) meetings of CPSUs and other meetings held in MoP/ CEA.

Elaborated guidelines dated 8 November, 2019 have been issued by Government of India to avoid time and cost overrun in Hydro ElectricProjects.

Following steps have been taken by the Government to enhanceproduction capacity of Hydro-Electric Projects:

Renovation & Modernisation, Uprating and Life Extension (RMU&LE) of the existing old Hydro-Electric Projects to augment(uprating) capacity addition in the country.

Government has taken several policy initiatives in the past to give a boost to hydro power development in the country viz.,National Electricity Policy 2005, Hydro Power Policy 2008, TariffPolicy, 2016, etc.

Govt. of India in March, 2019 approved a number of measures for promoting hydropower in the country and improving viability ofthe Sector. These include:

Declaring Large Hydro Power (LHPs) (> 25 MW projects) as Renewable Energy source.

Hydro Purchase Obligation

Tariff rationalization measures

Budgetary Support for Flood Moderation/Storage Hydro Electric Projects (HEPs).

Budgetary Support towards Cost of Enabling Infrastructure, i.e. roads/bridges.

Original post:
Production Capacity of Hydro Projects - Energy Sector News in India

Recommendation and review posted by Bethany Smith

Novel promoters based on those in the herpes viruses, enabled delivery of larger genes and increased the period they were active in the nervous system.

Novel promoter sequences have been developed to improve gene therapy treatments for neurological diseases. The researchers suggest these engineered promoters should allow for the delivery of both larger genes and also enable them to remain active for longer.

Esteban Engel, a researcher in viral neuroengineering in the Princeton Neuroscience Institute, US, and his team have developed new gene promoters for use in gene therapy. The practice of replacing faulty genes or adding additional functional ones to augment a deficit or damage is thought to be a promising strategy for treating many diseases, including neurodegenerative diseases like Parkinsons and Alzheimers.

To deliver these genes to the required cells, scientists often use viral vectors engineered viruses that cannot cause disease but have all the necessary viral machinery to enter human host cells. One of the most commonly used examples is adeno-associated virus (AAV), because it is relatively harmless.

Gene promoters are added into the viral genome alongside the desired gene in order to turn on their expression. To boost the efficacy of these promoters in the nervous system, Engel and his team adopted several attributes of herpes virus promoters, because the herpes viruses can persist for years in the body through establishing a chronic infection in the nervous system.

The team reported their promoters occupied much less space than existing ones, which could enable larger genes or multiple genes to be transported in the vectors. They also observed the new promoters are long-lasting, being less prone to repression or inactivation than most, so the therapeutic genes are active for long periods of time.

The team established that these novel promoters could work with AAVs as well as other viral and non-viral gene-delivery systems.

The research was published in the journalMolecular Therapy: Methods & Clinical Development.

Originally posted here:
Novel gene promoters could improve gene therapies - Drug Target Review

Recommendation and review posted by Bethany Smith

NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the European Medicines Agency (EMA) has granted Advanced Therapy Medicinal Product (ATMP) classification to MB-107, Mustangs lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (XSCID), also known as bubble boy disease. The U.S. Food and Drug Administration (FDA) previously granted Regenerative Medicine Advanced Therapy (RMAT) designation to MB-107 for the treatment of XSCID in August 2019.

EMA grants ATMP classifications to new therapeutics that are based on genes or cells and intended as long-term or permanent therapeutic solutions to acute or chronic human diseases at a genetic, cellular or tissue level. The ATMP program provides specific regulatory guidelines for preclinical development, manufacturing and product quality testing of ATMPs and offers incentives, including fee reductions for regulatory advice, recommendations and evaluation and certification of quality and non-clinical data.

Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, We are extremely encouraged that the EMA has granted MB-107 with ATMP classification, an important step in establishing our path to market approval and commercialization in Europe. This classification complements the RMAT designation we received last year from the FDA and brings us closer to realizing our goal of commercializing MB-107 for XSCID patients, as these patients are in desperate need of innovative and potentially curative treatment options.

MB-107 is currently being assessed in two Phase 1/2 clinical trials for XSCID: the first in newly diagnosed infants under the age of two at St. Jude Childrens Research Hospital (St. Jude), UCSF Benioff Childrens Hospital in San Francisco and Seattle Childrens Hospital and the second in patients over the age of two who have received prior hematopoietic stem cell transplantation at the National Institutes of Health. Under a licensing partnership with St. Jude, Mustang intends to develop the lentiviral gene therapy for commercial use as MB-107.

About Mustang BioMustang Bio, Inc. (Mustang) is a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission. Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit http://www.mustangbio.com.

ForwardLooking StatementsThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on managements current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Company Contacts:Jaclyn Jaffe and William BegienMustang Bio, Inc.(781) 652-4500ir@mustangbio.com

Investor Relations Contact:Daniel FerryLifeSci Advisors, LLC(617) 430-7576daniel@lifesciadvisors.com

Media Relations Contact:Tony Plohoros6 Degrees(908) 591-2839tplohoros@6degreespr.com

Original post:
Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked...

Recommendation and review posted by Bethany Smith